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Mortality from breast cancer is almost entirely the result of invasion and metastasis of 
neoplastic cells; therefore, understanding gene products involved in breast cancer 
metastasis is an important research goal. I discovered DP103, a RNA helicase, to be 
correlated with the level of maglinancies and its suppression led to the decrease in the 
ability of highly invasive breast cancer cells to migrate and invade. MMP9 is found to be 
a major matrix metalloproteinase involved in the degradation of the cell’s extracellular 
membrane to facilitate metastasis.  
 
A panel of breast cancer cell lines was screened for MMP9 expression. Interestingly, this 
screen shows cell lines that are highly metastatic such as MDA-MB-231 and BT549 
display high expression levels of MMP9 and they are highly correlated to DP103 levels. 
When grouping patients with positive DP103 expression to positive and negative MMP9 
expression, Kaplan-Meier correlation analysis show patients with positive DP103 and 
MMP9 expression have poorer survival outcomes (p=0.029).  
 
Next, using EMSA and luciferase reporter assay, it is shown that this decrease in MMP9 
levels is regulated by NF-κB and not AP-1. Additionally, under the stimulation of known 
NF-κB genotoxic agents, NF-κB activity was also decreased when DP103 was 
knockdown. I also discovered that DP103 coimmunoprecipitated with NEMO, an 
essential NF-κB modulator, and that it is required for the SUMOylation of NEMO upon 
genotoxic stress. Downregulation of DP103 abrogated this modification to occur. 
Additionally, it was observed that DP103 enhances the interaction of NEMO and PIASy, 
ix 
 
an E3 SUMO ligase, while decreasing that of NEMO and the specific desumoylating 
enzyme, SENP2.  
 
Using a clinically approved drug, a reduction of DP103 and cell invasion after statins 
treatment was observed. Importantly, forced expression of DP103 is able to rescue this 
inhibition of metastasis. The in vivo model using nude mice with MDA-MB-231 cells 
injected showed a reduction in metastases formed and DP103 expression when they are 
fed with simvastatin. 
 
Together, my study identifies DP103 as the “missing” key regulator of NF-B activation 
under genotoxic stress. Importantly, DP103 is a novel prognostic marker that identifies 
patients who are at risk for developing metastases, thus enabling oncologists to begin 
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CHAPTER 1  INTRODUCTION 
 
1.1 Breast Cancer 
 
1.1.1 Worldwide, Asia and ethnicity trends 
Breast cancer is one of the most common malignancies among women around the 
world. It is a complex disease that results from a multi-stage process involving the 
deregulation of a number of different signaling cascades. It is also the most frequent 
non-skin cancer to affect women worldwide, and remains one of the top public health 
burdens. Breast cancer accounts for nearly 1 in 3 cancers diagnosed among women in 
the United States. According to the American Cancer Society, approximately 230 480 
new cases of invasive breast cancer and 39 520 cancer deaths are expected to occur 
among women in United States in 2011. Changes in reproductive patterns such as 
delayed childbearing and having fewer children are recognized as risk factors for 
breast cancer (Desantis et al., 2011).  
 
The risk of getting cancer varies geographically. Despite having a lower breast cancer 
incidence rate compared to Western countries, the breast cancer risk has been 
increasing in most Asia countries. The age-standardized incidence rates of breast 
cancer increased from 32.5 per 100 000 women in 1983 to 35.0 per 100 000 in 2004 
and a further increase to 45.9 per 100 000 in 2008 for Asia women (Kwong et al., 
2011).  
 
 Amongst the highest in Asia, breast cancer is the leading cause of cancer death in 
Singaporean women for the past 30 years, with relatively large yearly variations 
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attributable to the relatively small female population (Shin et al., 2010). Currently, it 
accounts for 29.7% of all female cancers. About 1100 new cases are diagnosed 
annually and approximately 270 women die in Singapore each year from breast 
cancer, translating to breast cancer diagnoses in about three women daily, with 
approximately three cancer deaths every four days. The rate of increase in incidence 
in Singapore is also one of the highest in the world at 5.7% per year in premenopausal 
women and 3.9% per year in postmenopausal women, in contrast to only 1.5% per 
year in the United States (Jara-Lazaro et al., 2010). The risk of breast cancers across 
different ethnic groups differs in Singapore, with Singapore Indian women having the 
highest risk of 37.9 per 100 000 per year. Singapore Chinese and Malay women had a 
slightly lower risk of 28.3 and 34.3 per 100 000 per year (Singapore Cancer Registry, 
21 June 2011).  
 
 
1.1.2 Classifications of breast cancers 
Breast cancer, instead of constituting a monolithic entity, comprises of heterogeneous 
tumors with different clinical characteristics, disease courses, and responses to 
specific treatments. As such, breast cancers can be classified by difference schemata, 
as discussed below: 
 
Histopathology 
Histopathologic classification is based upon characteristics seen upon light 
microscopy of biopsy specimens. The majority of breast cancers are derived from the 
epithelium lining the ducts or lobules and are classified as mammary ductal 
carcinoma. Carcinoma in situ refers to the proliferation of cancer cells within the 
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epithelial tissue without invasion of the surrounding tissue. In contrast, invasive 
carcinoma invades the surrounding tissue. Invasive ductal carcinoma (IDC) is the 
most common type observed, representing 75% of all types of breast cancer, while 
invasive lobular carcinoma represents the next most frequent histologic type of breast 
tumor. Together, these two make up about 90% of breast cancers, while the remainder 
are categorized as medullary, neuroendocrine, tubular, apocrine, metaplastic, 
mucinous, inflammatory, comedo, adenoid cystic and micropapillary types (Li, 2005; 
Weigelt et al., 2010). 
 
Grading 
Grading focuses on the appearance of the breast cancer cells with reference to that of 
normal breast tissue. Well differentiated tissues are graded as low grade of a score of 
1, moderately differentiated as intermediate grade with a score of 2 and poorly 
differentiated as high grade with a score of 3 or 4, as the cells progressively lose the 
features seen in normal breast cells. The Nottingham modification of the Scarff-
Bloom-Richardson grading system is a commonly used scale, which grades breast 
carcinomas by adding up scores for tubule formation, nuclear pleomorphism and 
mitotic count, each of which is given 1 to 3 points. The scores for each of these three 
criteria are then added together to give an overall final score and corresponding grade 
(Bloom and Richardson, 1957; Genestie et al., 1998). 
 
Staging 
Breast cancers can also be classified according to the size of the cancers in the 
primary and secondary sites. The TNM classification for staging breast is developed 
and maintained by the International Union Against Cancer (UICC) to achieve 
4 
 
consensus on a globally recognized standard for classifying the extent of cancer 
spread. It also includes characteristics like nodal spread and metastasis. Stage 0 is a 
pre-cancerous condition, while stage 1 to 3 tumors are within the breast or regional 




Under this classification, breast cancers are categorized according to the status of 
three receptors, namely estrogen receptor (ER), progesterone receptor (PR) and 
human epidermal growth factor receptor 2 (HER2) receptor. Tumors with the absence 
of these three receptors are referred to triple-negative breast cancers (Bauer et al., 
2007). 
 
Intrinsic subtypes model 
Advances in gene expression analyses enabled a new classification of breast cancers 
by their molecular profiles into six intrinsic subtypes: luminal A, luminal B, HER2-
enriched, basal-like, normal breast-like and claudin-low (Eroles et al., 2012; Sorlie, 
2004). This new classification is based on a large scale analysis, using biological 
characteristics to group breast cancer tumors. The distinctive features of each subtype 








Subtype Freq ER/PR/HER2 Histologic 
grade 
Prognosis 
Basal-like 10-20% ER-, PR-,  HER2- High Bad 
HER2-enriched 10-15% ER-, PR-, HER2+ High Bad 
Normal breast-
like 
5-10% ER-/+ , HER2- Low Intermediate 
Luminal A 50-60% ER+, PR+, 
HER2- 
Low Excellent 
Luminal B 10-20% ER+/-, PR+/-, 
HER2-/+ 
High Intermediate/bad 
Claudin-low 12-14% ER-, PR-, Her2- High Bad 
Table 1: Features of intrinsic subtypes of breast cancer  
Treatments for Luminal A and B include aromatase inhibitors, selective estrogen 
receptor modulators and pure selective regulators of ER, though luminal B tumors 
respond better to neoadjuvant chemotherapy. Comparatively, HER2-enriched tumors 
have high chemosensitivity with higher response rate than luminal A and B tumors. 
Basal-like breast tumors posses worse prognosis than luminal subtypes and have 
higher relapse rate despite its high response to chemotherapy. The high incidence of 
p53 and BRCA1 mutations also led to genetic instability. Normal breast subtype, on 
the other hand, is considered rare and there are doubts about the real existence as it is 
thought to be a technical artifact from high contamination with normal tissue during 
microarrays. Claudin-low subtype is the last subtype to be identified and it is 
characterized by a low expression of genes involved in intercellular adhesion while 




1.1.3 Therapies for hormone-positive breast cancers 
Current therapies for the treatment of breast cancers revolve around the presence (or 
absence) of specific markers, namely ER, PR and HER2. Expressions of the first two 
receptors are determined by immunohistochemistry (IHC) from breast tissues, while 
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HER2 expressions are determined by both IHC and fluorescence in situ hybridization 
(FISH). ER status is used to segregate the hormone-positive breast cancer patients for 
treatment using anti-estrogen (endocrine) therapy.  
 
Estrogen is a hormone known to regulate menstruation in females. However, 
dysregulation of estrogen causes cancer by turning on hormone-responsive genes that 
promote DNA synthesis and cell proliferation. Endocrine therapy works to reduce the 
effect of estrogen on the body so that it can no longer turn on the growth of hormone-
receptor-positive breast cancer cells. Different treatments either block hormone 
receptors, eliminate hormone receptors or lower estrogen levels in the body. 
Tamoxifen, the ER modulator, improves survival among women with early and 
advanced breast cancer and further improvements are provided by aromatase 
inhibitors and the ER-degrading agent, fulvestrant (2005; Gibson et al., 2009; 
Gradishar, 2010; Robertson et al., 2009). Their long-term efficacy, however, is 
limited by relapse of disease and development of resistance. Despite continuous 
expression of ER at relapse in either locally recurrent or secondary metastatic tumors, 
up to 50% of patients with hormone-positive primary breast cancer who develop 
metastatic disease do not respond to first-line endocrine treatment, and the remainder 
will eventually relapse despite an initial response (Ring and Dowsett, 2004). 
 
The HER family of proteins are activated by numerous extracellular ligands, which 
dimerize upon binding, become phosphorylated, and transduce intracellular signals 
that regulate a variety of cellular processes. Patients who are HER2 positive are 
treated with targeted therapies like the monoclonal antibodies trastuzumab and 
lapatinib, which bind to HER2 and disrupt HER2-dependent signaling and trigger 
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antibody-dependent cytotoxicity (Kim et al., 2009; Valabrega et al., 2007). HER2 
overexpression confers intrinsic resistance to endocrine therapy, hence in tumors that 
are both HER2 and ER positive, they responded poorly to endocrine therapies (De 
Laurentiis et al., 2005; Lipton et al., 2002). Such resistance can be partially overcome 
by combining anti-estrogen and anti-HER2 therapies. In a randomized Phase III 
study, the addition of trastuzumab with an aromatase inhibitor improved outcomes for 
patients with metastatic breast tumors that expressed both ER and HER2 (Kaufman et 
al., 2009).  
 
In addition to approved agents, there are a number of novel strategies against HER2 
that have shown activity in tumors that have progressed during treatment. 
Trastuzumab-DM1 is an anti-HER2 antibody-drug conjugate that specifically 
recognizes HER2-positive tumor cells, thereby targeting them for degradation (Lewis 
Phillips et al., 2008). In a study of trastuzumab-DM1 versus trastuzumab plus 
docetaxel, trastuzumab showed similar efficacy to the combination with almost non-
existent side effects (Mathew and Perez, 2011).  
 
Resistance to anti-HER2 therapies can be due to cross-talk between the ER and HER 
themselves or between signaling pathways downstream of these receptors such as 
PI3K, Akt or mTOR (Prat and Baselga, 2008). A recent Phase Ib study therefore 
combined everolimus, a mTOR inhibitor, with paclitaxel and trastuzumab in patients 
with HER2-overxpressing metastatic breast cancer who were pretreated with 
trastuzumab (Andre et al., 2010). The overall response rate in 27 patients was 44%, 




1.1.4 Therapies for hormone-negative / triple-negative breast cancers 
Tumors with the absence of ER, PR or HER2 are known as triple-negative breast 
cancers and are predominantly of high histological grade and affect patients less than 
50 years old more frequently (Haffty et al., 2006; Thike et al., 2010). Triple-negative 
breast cancers are more prevalent in African-American women (Bauer et al., 2007), 
often present as interval cancers and are significantly more aggressive than tumors of 
other molecular subtypes (Dent et al., 2007; Rakha et al., 2007). This aggressiveness 
is best exemplified by the fact that the peak risk of recurrence is between the first and 
third years and the majority of deaths occur in the first 5 years following therapy. In 
contrast, the recurrence risk of non-triple negative group remained constant overtime. 
However, a substantial number of triple-negative cancer patients appear to be cured if 
they remain recurrence free for the first several years after diagnosis (Anderson et al., 
2006; Dent et al., 2007; Tischkowitz et al., 2007). Some key additional histological 
features of triple-negative tumors include increased mitotic activity and atypical 
mitotic figures, high Ki67 index, high nuclear-cytoplasmic ratio, pushing margins of 
invasion and stromal lymphocytic infiltration (Fulford et al., 2006; Livasy et al., 2006; 
Rakha et al., 2006). The metastatic spread of triple-negative tumors are reported to 
show specific patterns with a higher propensity for incidence of metastases to the 
brain and lungs and a lower incidence to the liver, bone and axillary lymph nodes 
(Fulford et al., 2007; Smid et al., 2008; Tsuda et al., 2000). 
 
While effective endocrine therapies exist for women with hormone receptor positive 
or HER2 positive breast cancers, chemotherapy is the only systemic therapy available 
for women with triple-negative disease besides surgery and radiation therapy. 
Anthracycline, an inhibitor of topoisomerase II and thereby causes DNA strand break, 
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is commonly used as a neo-adjuvant therapy for treatment of triple-negative breast 
cancers. In a study involving 255 patients with triple-negative breast cancer receiving 
anthracycline or anthracycline and taxane-based regimens, the pathological response 
rate of triple-negative tumor was 22% compared to that for non-triple negative 
cancers at 11% (Liedtke et al., 2008). In other studies, 17% of triple-negative cancers 
have been shown to have a pathological complete response after neo-adjuvant 
platinum-based chemotherapy (Sirohi et al., 2008).  
 
Germline BRCA1 mutations has been reported in a subset of triple-negative breast 
cancers (Collins et al., 2009; Turner et al., 2007; Young et al., 2009). Tumors with 
this mutations have defects in the DNA repair machinery and are highly sensitive to 
platinum-based drugs. For example, a neo-adjuvant trial of women with BRCA1 
mutations and triple-negative cancer showed a 90% complete pathological responses 
to a single agent cisplatin (Byrski et al., 2008). Another type of treatment involves the 
use of PARP inhibitors which prevent the repair of DNA single strand break upon 
damage. These inhibitors were initially developed to enhance the cytotoxicity of 
radiation and certain DNA-damaging agents (Farmer et al., 2005; Halmosi et al., 
2001). In recent years, they have been shown to have single-agent activity in some 
tumors. Inhibition of PARP in a DNA repair-deficient tumor can lead to gross 
genomic instability and cell death by exploiting the paradigm of synthetic lethality. 
Several studies have evaluated the role of PARP inhibitors for treatment of breast 
cancer, in the context of BRCA-mutated tumors and had shown effective results. In a 
study, olaparib (AstraZeneca), a PARP inhibitor was given to 54 patients with BRCA1 
or BRCA2 mutations and advanced breast cancers. The overall response rate was 41% 
among the 27 patients assigned to the drug without significant toxicity. These findings 
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were complemented by the impressive clinical benefit from 34% to 56% and the rate 
of overall response from 32% to 52% when iniparib (Sanofi), another PARP inhibitor 
was combined with carboplatin and gemcitabine in a randomized Phase II trial 
evaluating iniparib in patients with metastatic triple-negative breast cancers 
(O'Shaughnessy et al., 2011). The addition of iniparib also prolonged the median 
progression-free survival from 3.6 months to 5.9 months and the median overall 
survival from 7.7 months to 12.3 months. On the basis of these results, a Phase III 
trial is currently ongoing (http://clinicaltrials.gov/ct2/show/NCT00938652?term= 
NCT00938652&rank=1). A neo-adjuvant trial of women with BRCA1 mutations and 
triple-negative cancer showed a 90% complete pathological responses to a single 
agent cisplatin (Byrski et al., 2008). However, other studies showed that triple-
negative tumors did not show increased sensitivity to taxanes or platinum-based drugs 
(Chabalier et al., 2006; Rottenberg et al., 2007), indicating that these targeted 
therapies are still limited by the heterogeneity of breast cancers. 
 
There are a number of challenges that still need to be addressed in the treatment of 
triple-negative breast cancers. Besides the nature of such tumors, the identification of 
biomarkers of response and early markers of clinical benefits are necessary. The study 
of mechanisms of resistance to different therapies is also critically important. A 
frequent mechanism of resistance in breast cancers is the constitutive activation of 
NF-κB (Nakshatri et al., 1997; Wu and Kral, 2005). Therefore, knowledge of the 
mechanism of such resistance will benefit the search for candidate genes for targeted 
therapies. Ongoing research are focused on developing standardized and validated 
biomarkers that are able to indicate an early response (or lack thereof) to targeted 
agents in a variety of tumor types. These developments would have to be tested in 
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clinical patient samples before moving into clinical trials. All these efforts will help to 
define new prognostic and predictive markers to identify patients with triple-negative 


























Cancer metastasis is the multi-stage process by which cancer spreads from the place 
at which it first arose as a primary tumor to distant locations in the body. This process 
consists of sequential steps which are interconnected through a series of adhesive 
interactions and invasive processes. Due to its heterogeneity nature, mechanisms 
involving metastasis remain poorly understood. 
 
The steps involved in the metastatic cascade are shown in Figure 1. Firstly, 
development of a new blood supply to the growing tumor or angiogenesis occurs. 
This is then followed by the disaggregation of tumor cells from the primary tumor 
mass which then invade and migrate through the cell's basement membrane, as well as 
the extracellular matrix (ECM) surrounding the tumor epithelium and the blood 
vessels. The tumor cells then move into the blood vessel and travel to their secondary 
site. These circulating tumor cells subsequently adhere themselves to the endothelial 
cell lining at their target organ sites, invade through the ECM and surrounding 
basement membrane to the target organ tissue. After colonization, these tumor cells 
start to grow and develop their own blood vessels to support their growth (Steeg, 
2003).  
 
The principle sites of metastasis in breast cancers are the bone, lungs, liver and brain . 
The incidence of metastases to the brain and lungs is higher compared to the liver and 
bone for triple-negative breast cancers. This indicates a site specific preference which 



















1.2.1 Tumor Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing vasculature. It 
can occur under normal physiological conditions to aid wound healing or during 
pregnancy to provide the blood circulation between the mother and her fetus. The 
establishment of angiogenesis ensures that cell proliferation, migration and 
differentiation will occur subsequently. These require a balance of both pro-
angiogenic and anti-angiogenic factors. Angiogenin (Fett et al., 1985), fibroblast 
growth factor (Gospodarowicz, 1976), interleukin-8 (Smith et al., 1994), placental 
growth factor (Takahashi et al., 1994), platelet-derived growth factor (Ishikawa et al., 
1989), transforming growth factor α and β (Falcone et al., 1993) and vascular 
endothelial growth factor (Takahashi et al., 1994) are some examples of genes that 
promote angiogenesis. On the other hand, anti-angiogenic factors include endostatin, 
human chorionic gonadotrophin, interferon α, β and γ, thrombospondin-1, tissue 
inhibitors of matrix metalloproteinases and vasostatin (Bridges and Harris, 2011; 
Sharma et al., 2011; Zogakis and Libutti, 2001). Deregulation of these genes will 
disrupt the balance and favor persistent angiogenesis to occur, resulting in diseases 
like diabetic retinopathy (Murata et al., 1995), rheumatoid arthritis (Folkman, 1995), 
age-related macular degeneration (Lip et al., 2001) and cancers (Folkman, 1995).  
 
 
1.2.2 Disaggregation of cells from primary tumor 
Loss of cell-cell adhesion within the primary tumor mass permits the disaggregation 
of tumor cells and hence aids initial dissemination. Compared with normal epithelial 
cells, cancer cells show diminished cell-cell adhesiveness (Cavallaro and Christofori, 
2004). Cadherins are a large family of adhesion molecules that interact with the actin 
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component of the cytoskeleton and are involved in maintaining the tight intercelluar 
adhesion interactions (Angst et al., 2001). Abrogation of E-Cadherin had been shown 
to be associated with the metastatic phenotype in cancers (Christofori and Semb, 
1999; Perl et al., 1998). The down-regulation of E-Cadherin has also been reported in 
vivo in breast cancers (Meyer and Hart, 1998; Perl et al., 1998). Additionally, catenin 
was shown to be required for cell-cell adhesion as the lack of it resulted in weak 
adhesion (Watabe et al., 1994). 
 
 
1.2.3 Invasion and ECM degradation 
Invasion is the active translocation of neoplastic cells across tissue boundaries and 
through host cellular and ECM barriers. It is dependent on the concerted efforts of 
several proteins from within the cell to cell surfaces as well as the external 
microenvironment. The family of cell-cell adhesion receptors (CAMs) has been 
widely studied for their role in cancer invasion. For example, intercellular adhesion 
molecules (ICAMs), L-, E- and P-selectins, vascular cell adhesion molecules 
(VCAMs) and neural cell adhesion molecules (NCAMs) have all been reported to be 
overexpressed in metastatic cancers (Buitrago et al., 2011; Johnson, 1999; Yamaoka 
et al., 2011). 
 
Under normal physiological conditions, proteolysis of ECM is seen during wound 
healing, tissue remodelling, embryo morphogenesis and trophoblast implantation 
(Curran and Murray, 2000). Degradation of the ECM by matrix metalloproteinases 
(MMPs) is essential for almost every step in metastasis, for example in aiding cells 
crossing the ECM barriers and the epithelial membrane as well as facilitating 
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intravasation, extravasation and colonization at distant sites (Egeblad and Werb, 
2002). A tilt in the delicate balance in the regulation of proteases and protease 
inhibitors can cause uncontrollable invasion to occur.  
 
The family of MMPs is one of the major enzymes that degrade the ECM. So far, there 
are at least 24 different MMPs known to exist in the mammalian systems (Curran and 
Murray, 2000; Klein and Bischoff, 2011). All the MMPs possess specific domains 
that are conserved between different members. The presence of zinc ions at the 
catalytic active site determine the enzyme's activity (Klein and Bischoff, 2011). Most 
MMPs are synthesized and secreted in a zymogen form (pro-enzyme) and activation 
of the enzyme is necessary to cleave off a 10kDa amino-terminal domain (Baramova 
et al., 1994). Based on their domain organisation and substrate specificity, the 
members of this family are divided into 4 subgroups, namely (i) interstitial 
collagenases; (ii) gelatinases; (iii) stromelysins and (iv) membrane-type MMPs. The 
collagenases subgroup consist of MMP1, MMP8 and MMP13. These MMPs catalyse 
the degradation of fibrillar forms of collagen.  
 
 
1.2.4 Gelatinases or Type IV collagenases 
The gelatinases, also known as type IV collagenases, degrade gelatin and types IV, V, 
VII, IX and X collagen, of which type IV collagen being the most abundant in the 
basement membranes. MMP2 (gelatinase A) and MMP9 (gelatinase B) are the two 
members in this subgroup (Deryugina and Quigley, 2006). They are thought to have 
similar substrate specificity with respect to ECM substrates, but different towards 
growth factor receptors (Levi et al., 1996). Besides degradation of the ECM and 
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basement membrane, MMPs also aid in the release of growth factors, for instance 
VEGF and fibroblast growth factor (FGF), which then stimulate angiogenesis (Curran 
and Murray, 2000). However, how MMPs can mediate these regulations remain 
unknown. 
 
There have been many evidence over the decades documenting the association of 
MMPs in the process of tumorigenesis and metastasis. For instance, back in the 
1990s, it was already shown that MMP2 and MMP9 are highly expressed in invasive 
colon, gastric, ovarian and thyroid adenocarcinomas compared to normal colorectal, 
gastric mucosa and benign ovarian cysts (Levy et al., 1991; Liu et al., 2010; 
Monteagudo et al., 1990). In a recent study, the immunohistochemical expression of 
MMP2 and MMP9 and the correlation between their expression levels and prognostic 
clinicopathological parameters were investigated in 140 patients with IDC (Sullu et 
al., 2011). Their study showed that MMP9 staining was the strongest in high grade, 
triple-negative and ER-negative tumors and tumors with distant metastases. At the 
same time, it was known that high MMP9 expression was associated with a shorter 
disease-free survival and overall survival times, hence indicating high MMP9 
expression is related to poor prognostic clinicopathological factors in IDC. On the 
other hand, MMP2 expression did not show consistent nor significant findings. In 
another study, high serum levels of MMP9 are linked to rapid progression, poor 
overall survival and secondary metastasis in cancer patients with melanoma (Nikkola 







Proteolytic activity of MMPs are inhibited by tissue inhibitors of metalloproteinases 
(TIMPs). They perform their function by forming high-affinity 1:1 stoichiometric, 
non-covalent complexes with the active MMPs (Baramova et al., 1994; Deryugina 
and Quigley, 2006). There are four members in the TIMP family, namely TIMP1, 2, 3 
and 4. Each of their N- and C-terminal domains contains six conserved cysteine 
residues that form three disulfide loops (Stetler-Stevenson, 2008). The N-terminal 
region binds to the MMPs' catalytic domain and inhibits MMP activity, whereas the 
C-terminal region interacts with the pro-forms of MMP2 and MMP9 C-terminal 
hemopexin domain to stabilize the proenzyme inhibitor complex. TIMPs are able to 
inhibit all active MMPs, but not with the same efficacy. TIMP1 preferentially inhibits 
MMP1, MMP3, MMP7 and MMP9 while TIMP2 is more effective in inhibiting 
MMP2. TIMP3 can inhibit MMP2 and MMP9, while TIMP4 inhibits MMP2 catalytic 
activity (Bourboulia and Stetler-Stevenson, 2010). 
 
Besides being the inhibitors of MMPs, TIMPs are also revealed to be involved in 
several biological activities including cell differentiation, angiogenesis and apoptosis 
(Brew and Nagase, 2010; Stetler-Stevenson, 2008). TIMP2 inhibits the endothelial 
cell growth in vitro and angiogenesis in vivo upon stimulation with endothelial growth 
factors, VEGF-A or FGF-2. The identified mechanism is independent of TIMP2-







1.2.6 MMPs as targets in anti-metastatic therapies 
Due to the strong and direct association of MMPs in breast cancers, an inhibition of 
the enzyme's activity and function will help to inhibit tumor metastasis. However, due 
to their multiplicity and widespread effects of their actions, TIMPs cannot be used as 
an anti-cancer target. Hence, most research has focused on synthetic inhibitors. 
Different types of synthetic MMPs inhibitors like peptidomimetics, non-
peptidomimetics inhibitors, tetracycline derivatives target MMPs in the extracellular 
space (Brown, 2000; Overall and Lopez-Otin, 2002). Some used antisense and small 
interfering RNA (siRNA) to selectively decrease the level of mRNA of a specific 
MMP. However, targeted delivery of these oligonucleotides to the tumor site poses a 
huge problem (Brown, 2000). Systemic use of siRNA for therapies is still 
controversial due to the limitations of siRNA such as low enzymatic tolerability, 
cellular internalization and body distribution after systemic administration (Guo et al., 
2010; Pirollo and Chang, 2008; Tamura and Nagasaki, 2010). 
 
Marimastat, a broad spectrum peptidomimetic MMPs inhibitor, mimics the peptide 
structure of natural MMP substrates and binds to MMPs, thereby preventing the 
degradation of the basement membrane by these proteases. It was found to show 
significant increase in survival in patients with early stage, metastasis-free disease 
(Bramhall et al., 2001). However, this drug has side effects like musculoskeletal 
syndrome which requires attention for patients on this treatment. Non-peptidomimetic 
MMPs inhibitors like BAY12-9566, prinomastat and BMS-275291 are synthesized 
based on the crystal structure of the active site of MMPs to improve specificity and 
oral bioavailability compared to peptidomimetic inhibitors (Price et al., 1999; Tonn et 
al., 1999). However, they also met with limited efficacy and side effects in several 
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clinical trials. The trial involving the use of BAY12-9566 in patients with small cell 
lung cancer showed a significant increase in both disease progression and mortality in 
the treated group when compared with placebo (Brown, 2000). The side effects of 
marimastat are characterised as a musculoskeletal syndrome which persists if patients 
continue to take the drug in the face of symptoms (Moore et al., 2003). 
 
 Another generation of MMPs inhibitors, tetracycline derivatives, inhibit the 
enzymatic activity of MMPs as well as blocking the transcription of MMPs. Metastat 
(COL-3), minocycline and doxycycline are some members in this family of inhibitors. 
Their toxicity level are lower and doxycycline is currently the only Food and Drug 
Administration (FDA) approved MMPs inhibitor for the prevention of periodontitis 
(Sapadin and Fleischmajer, 2006). However, its effect on the treatment of metastatic 
breast cancer remains unknown. 
 
A major limitation in using MMP inhibitors in cancer therapy is the method of 
evaluation of their efficacy in clinical trials. Traditional readouts such as tumor size, 
proliferation and apoptosis markers are not likely to be affected by anti-invasive 
strategies. Metastatic progression of a cancer is also a very indirect readout of cell 
invasion and cannot be easily assessed in phase I and II trials with patients who are 
already in their advanced stage of cancer (Overall and Lopez-Otin, 2002). The multi-
level complexities of the process of metastasis from the first step of angiogenesis to 
the last step of development of the secondary tumor makes it difficult to determine 




A shift in the mindset to profile a tumor could be important. Besides evaluating a 
tumor histopathologicaly and genetically, the susceptibility of a tumor towards 
metastasis could serve as a prognostic framework for targeted treatments. Hence, the 
desire to identify good prognostic and predictive markers for metastatic breast cancers 























1.3 DEAD/DExD Box Family 
RNA and DNA helicases are enzymes that catalyze the separation of double-stranded 
nucleic acids in an energy-dependent manner. They utilise the free energy change of 
binding and hydrolyse a nucleotide triphosphate to dissociate duplexes or displace 
bound proteins. Helicases are classified into three superfamilies and two families by 
the occurrence and characteristics of conserved motifs in the primary sequence.  
 
DEAD-box and the related DEAH, DExH and DExD families belong to the 
superfamily 2 of the RNA helicases. They share eight conserved motifs (Tanner and 
Linder, 2001), but can be differentiated by variations within them. The DEAD-box 
family is the largest of the superfamily and is characterised by the presence of nine 
conserved motifs. Over 40 members of the DEAD-box family have been isolated 
from a variety of organisms including bacteria, yeast, insects, amphibians, mammals, 
and plants (Jankowsky and Jankowsky, 2000; Linder and Slonimski, 1989). The 
conserved motifs in DExD/H helicases are clustered in a 'central' core region that is 
about 350 to 400 amino acids long, while DEAD box helicase members have a 
characteristic amino acid sequence Asp-Glu-Ala-Asp (D-E-A-D) in the Walker B 
motif, hence their name is dervied. Motif A (AXXGXGKS/T) has an ATPase activity. 




complex (Wittinghofer and Pai, 1991). Motif III is 
defined as having a helicase function and Motif VI has been thought to bind nuclei 
acids (Korolev et al., 1998).  
 
DEAD-box proteins commonly display ATP-dependent RNA helicase activity 
(Crawford et al., 1997) and have been shown to have important roles in cell 
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development, differentiation and proliferation. Although some DEAD-box proteins 
play general roles in cellular processes such as translation initiation (eukaryotic 
initiation factor 4A (Rozen et al., 1990)), RNA splicing (PRP5, PRP28, and SPP81 in 
yeast (Dalbadie-McFarland and Abelson, 1990; Jamieson et al., 1991; Strauss and 
Guthrie, 1994)), and ribosomal assembly (SrmB in Escherichia coli (Nishi et al., 
1988)), the function of most DEAD-box proteins remains unknown. 
 
 
1.3.1 Roles of DEAD-box proteins 
DEAD-box proteins are involved in the regulation of many processes involving RNA, 
from transcription level to degradation as shown in Figure 2.  
 





Firstly, some DEAD-box proteins are found to be associated with gene transcription. 
For instance, DP103 is found to be a co-repressor in transcription of several genes, 
which will be discussed extensively in chapter 1.4. Other DEAD-box members p68 
and p72 which are highly related to each other but also having distinct non-
overlapping functions, were found to be coactivators and corepressors of 
transcription. p68/p72 both act as a coactivator for ERα (Endoh et al., 1999; 
Watanabe et al., 2001; Wilson et al., 2004). Later, it was discovered that p68/p72 
interacts with the histone acetyltransferases CREB binding site (CBP)/p300, 
indicating p68 and p72 to be important components in the transcription machinery 
(Fujita et al., 2003). They also function as corepressors during their interaction with 
HDAC1 (Wilson et al., 2004). Interestingly, p68 acts as a coactivator of the 
transcriptional function of p53 in response to DNA damage (Bates et al., 2005), but 
represses p53-dependent expression of Δ133 p53 isoform (Moore et al., 2010). 
 
Another function of DEAD-box proteins involves splicing of pre-mRNA. Prp5 is 
found to be required in the early stages of pre-spliceosome assembly (Xu et al., 2004) 
while p68, Sub2/UAP56, Ded1 and Prp28 are involved in the progression towards the 
active spliceosome (Rocak and Linder, 2004).  
 
Ribosome biogenesis marks another function of DEAD-box proteins and a large 
number of them are associated with rRNA maturation in eukaryotes and prokaryotes 
(de la Cruz et al., 1999). However, their precise role during ribosome biogenesis is not 
known though some suggest that they have an RNA-RNA rearrangement activity in 
vivo, on top of their bona fide ATPases and helicases activity (Nicol and Fuller-Pace, 
1995; Rocak et al., 2005). 
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Several DEAD-box proteins are associated with the export of mRNA through the 
nuclear pore. One of them is Dbp5, which binds RNA cotranscriptionaly. It interacts 
with the nuclear pore complex and shuttles between the nucleus and cytoplasm 
(Weirich et al., 2004; Zhao et al., 2002). On the other hand, eIF4A and Ded1 from S. 
cerevisiae are found to be essential for translation initiation (Linder, 2003). 
 
 
1.3.2 DEAD-box proteins in cancers 
There has not been many reports on the relevance of members of the DEAD-box 
family on cancers. Of those that were reported, most of the DEAD-box proteins are 
upregulated in different cancers. However, the mechanisms behind this upregulation 
are not elucidated. 
 
Both p68 and p72 are found to be overexpressed in colon adenomas and carcinomas, 
with p68 being ubiquitinated in these tumors (Causevic et al., 2001; Shin et al., 2007). 
Furthermore, proliferation and the ability to form tumors in vivo were greatly 
decreased when both p68 and p72 were suppressed (Shin et al., 2007). p68 is also 
overexpressed in prostate cancer and is associated with higher tumor grades and poor 
prognosis in patients (Clark et al., 2008). p68 is involved in aberrant post-translational 
modification, whereby its phosphorylation is associated with cancer development, but 
this is not seen in p72 (Yang et al., 2007). More studies will need to be carried out to 





Ddx3, on the other hand, is involved in the transformation of epithelial to 
mesenchymal transition. It was also shown to promote cell motility and invasion, as 
well as the ability to form colonies in soft agar, via the downregulation of the 
expression of the cell adhesion molecule E-cadherin (Botlagunta et al., 2008). 
p21
waf1/cip1
 was subsequently identified to be a target gene of Ddx3, and the up-
regulation of p21
waf1/cip1 
expression accounted for the colony-suppressing activity of 
Ddx3, all of which are independent of its helicase activity. Furthermore, a declined 
expression of Ddx3 mRNA and protein was found in a significant number of 





of p53 status. All these suggest that Ddx3 might be a candidate tumor suppressor gene 
(Chao et al., 2006).  
 
In hereditary, non-hereditary retinoblastoma (RB) and neuroblastoma, both copies of 
the RB1 gene were shown to be mutated (Bookstein et al., 1988). MYCN oncogene 
amplification is also required for the formation of these malignant tumors (Schwab, 
1991). Ddx1 is often found to be co-amplified with MYCN in both of these childhood 
tumors (Godbout et al., 1998). A tissue microarray from 176 primary breast cancer 
samples found Ddx1 to be overexpressed and half of the patient cohort had 
experienced early relapse despite standard adjuvant therapy. They observed 
cytoplasmic staining of Ddx1 which was thought to be a nuclear enzyme, hence 
associating this with the early recurrence in patients with breast cancer (Germain et 
al., 2011). However, the authors failed to provide validation for their microarray data 
by alternative technology such as qPCR. Instead they provided data through their use 
of matched tissue microarrays from a subset of the initial cohort. Despite this, the 
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authors did not show any correlative data between Ddx1 mRNA expression and Ddx1 
cytoplasmic staining (Balko and Arteaga, 2011). 
 
Another DEAD box member, Ddx48 was identified as a novel autoantigen in 2005 
(Xia et al., 2005). ELISA results using patients sera showed that humoral response 
directed against Ddx48 occurred in 33.33% of pancreatic cancer patients, 10% in 
colorectal cancer patients, 6.67%  in gastric cancer patients and 6.67% in 
hepatocellular cancer patients. None of the sera from patients with chronic 



















1.4 DP103 / Ddx20 / Gemin 3 
DP103 (also termed Gemin3 and DDX20) is a member of the DEAD-box family of 
helicases. It is a protein of 824 amino acids that contains the DEAD-box motif at its N 
terminus (Figure 3) and had been cloned by several groups (Campbell et al., 2000; 
Charroux et al., 1999; Grundhoff et al., 1999; Ou et al., 2001).  
 
 
Figure 3. Pictorial representation of DP103 showing different motifs (Adapted 
from Ou et al., 2001). 
 
DP103 was first characterised by Grundhoff and group in 1999 and they showed 
DP103 interacts directly with Epstein-Barr virus nuclear antigens EBNA2 and 
EBNA3C which regulates transcription of both latent viral and cellular genes. This 
103kDa protein was observed in EBV-positive and EBV-negative B cell lines as well 
as in the T-cell line Jurkat, in SK-NS-H neuroblastoma cells and HeLa cells. The N-
terminal and C-terminal of DP103 do not show any significant homology to other 
proteins within or outside the DEAD box family, hence suggesting a possible 
specialised role of these regions of DP103. The C-terminal region was shown to 
interact with EBNA2 and EBNA3C, another indication that the C-terminal region 
may be important in mediating its interaction with other cellular proteins, for example 
cofactors. DP103 was almost exclusively found in the soluble nuclear fractions in 
these cell lines. Additionally, in a panel of human tissues, DP103 gene expression was 
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found to be low in colon, skeletal muscle, liver, kidney and lung, but very strong 
expression in primary malignant melanoma tumor samples, an indication that DP103 
may be highly expressed in proliferating cells (Grundhoff et al., 1999). 
 
DP103 was then found to interact with the spinal muscular atrophy protein, SMN to 
modulate gene expression. SMN is part of a multiprotein complex and together with 
SIP1 (SMN interacting protein 1), they are concentrated in gems bodies. SMN and 
SIP1 are important for the assembly of small nuclear ribonucleoproteins (snRNPs) 
(Liu et al., 1997), where Sm proteins combine with snRNAs that are exported from 
the nucleus. Once properly assembled and modified, the snRNPs recruit the necessary 
nuclear import receptors and translocate into the nucleus where they function in pre-
mRNA splicing (Zieve and Sauterer, 1990). Importantly, DP103 was found to co-
localise with SMN in gems, with its C-terminal mediating the interaction (Charroux et 
al., 1999).  
 
More information about the function of DP103 was unveiled in 2001 when Ou et al 
discovered DP103 to be a regulator of steroidogenic factor-1 (SF-1) which is essential 
for development of the gonads, adrenal gland and the ventromedial hypothalamic 
nucleus. SF-1 plays a pivotal role in regulating the expressions of steroidogenic 
enzymes and proteins in the endocrine and reproductive system. The loss of this 
protein results in abnormal gonadotrope differentiation, phenotypic male-to-female 
sex reversal, low serum levels of corticosteroids and early neonatal death (Luo et al., 
1994; Shinoda et al., 1995). In this aspect, DP103 acts to repress the transcriptional 
activity of SF-1, thereby down-regulating SF-1 target genes during development and 
function of reproductive and steroid-producing tissues. At the same time, they 
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deduced that it is the C-terminal region of DP103 that is capable of repressing the 
transcriptional activity. Additionally, the RNA helicase activity of DP103 is 
dispensable for the repression influence. Post-translational modifications were then 
found to be able to modulate the receptor activity. Phosphorylation of SF-1 is thought 
to increase the receptor activity while SUMOylation will result in transcriptional 
repression (The mechanism of SUMOylation will be covered in chapter 1.5). 
Interestingly, DP103 was found to promote PIAS-mediated SUMOylation of SF-1 
(Lee et al., 2005b), bringing to light for the first time a functional mechanism for the 
repressive ability of DP103. The importance of DP103 was amplified when Mouillet 
and group showed that homozygous DP103-null mice die early in embryonic 
development, before a four-cell stage. At the same time, although heterozygous mice 
are healthy and fertile, the females have larger ovaries, altered estrous cycle and 
reduced basal secretion of adrenocorticotopic hormone (ACTH) (Mouillet et al., 
2008). 
 
DP103 acting as a co-repressor was again demonstrated in macrophages. Induction of 
Ets repressor METS during macrophage differentiation contributes to terminal cell 
cycle arrest by repressing the transcription of cell cycle control genes like c-Myc, c-
Myb and Cdc2. METS selectively repress Ets target genes involved in Ras-dependent 
proliferation, but does not repress genes that are targets of Ras-dependent 
differentiation. DP103 was found to be co-immunoprecipitated with METS, and 
subsequently elucidated that the C-terminal domain of DP103 interacts with METS 
directly and is important for the anti-proliferative effects (Klappacher et al., 2002). 
However, the mechanisms responsible for this repression remained uncovered. DP103 
was also found to interact with and repress the Early Growth Response 2 (Egr2/Krox-
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20) transcription factor, which is important for myelination of the peripheral nervous 
system and for establishing segmentation in the developing vertebrate hindbrain 
(Gillian and Svaren, 2004). The transcriptional repression by DP103 was postulated to 
act through the recruitment of histone deacetylases (HDAC) as DP103 was shown to 
co-immunoprecipitate with HDAC2 and HDAC5 (Klappacher et al., 2002). DP103 
therefore demonstrates intrinsic transcriptional repression activity through direct 
interaction with various proteins. Its role as a transcriptional coactivator, on the other 
hand, remain elusive. 
 
Despite the above studies on the functions of DP103, its connection to cancer was 
unknown, until a study done in 2005. A protein microarray was done on mantle-cell 
lymphoma patients and showed an increase in DP103 expression in these patients 
(Ghobrial et al., 2005). Furthermore, in another microarray data done on colorectal 
cancer (CRC) patients' tissues, when comparing gene expression profile in primary 
tumors with and without distant metastases, DP103 expression is found to be 
upregulated in CRC patients that developed distant metastases (n=100; p<1 × 10
-10
, 
http://www.ebi.ac.uk/arrayexpress [Array express ID: E-GEOD-18105]). These point 
to a high possibility of the association of DP103 not only to cancer, but also possible 
anew marker for metastasis. 
 
The link between DP103 to metastasis was further strengthened in a recent United 
States Patent Application by Chan et al. published in 2010 on the use of compounds 
that block cancer metastasis showed DP103 as the only DEAD-box helicase member 
to be a potential target listed in the patent from their microarray data (Publication 
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Number: US 2010/0004190 A1). These suggest a possible role of DP103 in 




























1.5.1 The SUMO family 
SUMO (Small ubiquitin-related modifier) was discovered to be a reversible post-
translational protein modifier in the late 1990s. SUMO proteins are ubiquitously 
expressed in eukaryotes. In yeast, the SUMO homologue is called SMT3 (suppressor 
of mitf two 3). Other organisms, like plants and vertebrates, have several SUMO 
genes.  
 
In humans, there are 4 distinct members, namely SUMO1, SUMO2, SUMO3 and 
SUMO4. These proteins are about 12kDa in size and resemble the three-dimensional 
structure of ubiquitin (Bayer et al., 1998). Though so, there is less than 20% 
similarities in the amino acid sequences with ubiquitin and are different in their 
overall surface-charge distribution. On top of that, SUMO proteins have an 
unstructured stretch of 10-25 amino acids at their N-terminal that is not found in any 
other ubiquitin-related proteins. So far, the only function for this N-terminal tail is the 
formation of the SUMO chains. SUMO1, SUMO2 and SUMO3 are ubiquitously 
expressed throughout the organism, whereas SUMO4 seems to be expressed mainly in 
the kidney, spleen and lymph node (Guo et al., 2004).  
 
SUMO proteins are expressed in an immature form, where they have a C-terminal 
stretch of amino acids of varying lengths after the Gly-Gly motif. SUMO-specific 
proteases like sentrin-specific proteases (SENPs) cleave away this extension for 
conjugation of SUMO to its targets to occur. The mature forms of SUMO2 and 
SUMO3 are 97% identical, but only share 50% sequence homology with SUMO1. 
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And thus, SUMO1 and SUMO2/3 are described to serve distinct functions with 
conjugation to different target proteins (Rosas-Acosta et al., 2005; Saitoh and 
Hinchey, 2000). SUMO4, on the other hand, is not widely studied and is unclear 
whether it can be cleaved into the mature form in vivo and if it is functional (Guo et 
al., 2004; Owerbach et al., 2005). 
 
SUMOylation is an essential process in most organisms. For example, disruption of 
SUMO1 in mice led to embryonic lethality and SUMO1 haploinsufficiency resulted 
in split lip and palate in mice, an indication of possible developemental defects 
(Alkuraya et al., 2006). 
 
 
1.5.2 The SUMOylation pathway 
SUMOylation is directed by an enzymatic cascade analogous to that in ubiquitination. 
The SUMOylated pathway is outlined in Figure 4. The first step of SUMOylation is 
the activation of a mature SUMO protein, as mentioned earlier, by the SUMO-specific 
E1 activating enzyme heterodimeric AOS1-UBA2 (Desterro et al., 1999; Okuma et 
al., 1999). The C-terminal of this mature form has a diglycine motif that is required 
for the effective adenylation by the SUMO E1 enzyme. Once formed, the SUMO 
adenylate is attacked by a conserved Cys on the E1 enzyme to form an E1-SUMO 
thioester, which is then transferred to a conserved Cys on a SUMO E2 enzyme, 
thereby generating an E2-SUMO thioester. The E2 conjugating enzyme for 
SUMOylation is Ubc9, which is the one and only E2 enzyme known thus far. Many 
SUMO-modified proteins contain an acceptor Lys within a ψKX(D/E) consensus 
motif, where ψ is a large hydrophobic residue (Rodriguez et al., 2001). These residues 
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directly interacts with Ubc9 and have a critical role in regulating the stability of 
interactions between the E2 enzyme and the substrate (Sampson et al., 2001). Finally, 
Ubc9 transfers SUMO to the substrate, an isopeptide bond is formed between the C-
terminal Gly residue of SUMO and a Lys side chain of the target, catalysed by the 
SUMO E3 ligases .  
 
SUMO E3 ligases are characterised by the presence of the SP-RING motif. SP-RING 
ligases bind their targets and Ubc9 directly and bind SUMO non-covalently via a 
SUMO-interacting motif (SIM). One of the subgroups of SP-RING ligases is the 
family of PIAS (protein inhibitor of activated STAT) proteins. In humans, the 
members include PIAS1, PIAS3, PIASxα, PIASxβ and PIASy. Other subgroups of 
SP-RING ligases include MMS21 or NSE2 which is part of an octameric SMC5-
SMC6 complex essential for DNA repair and vegetative growth and also telomerase-
independent mechanisms of telomere lengthening in alternative lengthening of 
telomeres (ALT) cells (Potts and Yu, 2007). The third class of SUMO E3 ligases is 
the human Polycomb group member Pc2. Polycomb group proteins (PcG) form PcG 
bodies which are involved in gene silencing. 
 
PIAS family members are the best known E3 ligases for the process of SUMOylation 
and were initially identified in studies for understanding the JAK/STAT pathway 
(Chung et al., 1997; Liu et al., 1998). PIAS1, PIAS3 and PIASx were shown to 
interact with STAT1, STAT3 and STAT4 respectively (Arora et al., 2003; Chung et 
al., 1997; Liu et al., 1998), resulting in the inhibition of STAT-mediated gene 
activation. Subsequently, studies showed that this inhibition is brought about by the 
SUMOylation of STAT1, strongly enhanced by PIAS proteins (Rogers et al., 2003). 
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This post-translational modification is critical in the STAT pathway for the proper 
regulation of cytokine signaling pathways (Shuai, 2006). 
 
PIAS proteins have also been revealed to be required in the regulation of NF-κB 
pathway. Both PIAS1 and PIAS3 had been observed to interact with p65, thereby 
repressing its transcriptional activity (Jang et al., 2004; Liu et al., 2005). In addition, 
PIASy was shown to interact with NEMO to enhance its SUMOylation under 




Figure 4. The mechanism of SUMOylation. (Adapted from Katharina Maderböck 






Usually, SUMOylation results in the addition of a single SUMO protein to individual 
acceptor Lys residues. However, the formation of polySUMO chains has been 
observed both in vivo and in vitro. For example, in mammalian, SAE1/SAE2 and 
Ubc9 catalyze the formation of polymeric chains of SUMO2 and SUMO3 on protein 
substrates in vitro and SUMO2 chains are detected in vivo (Tatham et al., 2001). 
However, this ability is not shared by SUMO1, reiterating that modifications by 
SUMO1 and SUMO2/3 may have distinct functional consequences. 
 
Proteases are required for the deSUMOylation of substrates from the SUMO groups. 
So far, a single gene family that encodes SUMO-specific Cys proteases has been 
identified. In yeasts, they are Ulp1 and Ulp2 (Li and Hochstrasser, 1999; Li and 
Hochstrasser, 2000) and in humans, the homologues are sentrin-specific proteases, 
SENPs. There are six members in this family, namely SENP1, SENP2, SENP3, 
SENP5, SENP6 and SENP7 (There is no SENP4). SENP proteins are also required 
for the maturation of newly synthesized SUMO proteins. Members in this family 
differ in their activity in maturation, isopeptide cleavage and also their activity 
towards different SUMO proteins. SENP3 and SENP5 prefer to deSUMOylate 
SUMO2/3 from substrates (Di Bacco et al., 2006). In terms of localisation, SENP2 
complexes with nuclear pore proteins (Zhang et al., 2002) while SENP5 is enriched in 
the nucleolus. SENP1, on the other hand, shuttles between cytoplasm and the nucleus 







1.5.3 The SUMOylation consequences 
In contrast to ubiquitin, SUMO is not used to tag proteins for degradation. 
SUMOylation can promote or inhibit the formation of specific protein complexes, 
affect subnuclear localization of proteins and regulate transcription positively and/or 
negatively (Hay, 2005).  
 
Generally, there are three consequences for a modified protein. Firstly, SUMOylation 
can interfere with the interaction between the target and its partner. For instance, 
SUMOylated p300 interacts with HDAC6, resulting in transcriptional repression 
(Girdwood et al., 2003). SUMOylation of p68, on the other hand, was enhanced by 
the presence of PIAS1, which in turn can act as a transcriptional co-activator or a co-
repressor (Bates et al., 2005; Caretti et al., 2006). 
 
Secondly, SUMOylation provides a binding site for an interacting partner, typically 
via a non-covalent SUMO-interaction/binding motif (SIM/SBM). Daxx is one of the 
very few proteins to possess a SIM/SBM motif and findings showed that Daxx 
requires this non-covalent SUMO interaction for repression (Kuo et al., 2005).  
 
Lastly, SUMOylation can result in a conformational change of the modified target. A 
known example is the SUMOylation of DNA-repair enzyme thymine DNA 
glycosylase (TDG). TDG recognizes and binds to a mismatch on DNA and excises 
the corrupted base. However, TDG binds tightly to the reaction product, with which 
SUMOylation of TDG helps to reduce the DNA affinity via a conformational change. 




1.5.4 SUMOylation, cancer progression and metastasis 
The SUMOylation process is involved in several aspects of cancer including the onset 
of tumor formation to metastasis. Here, I shall discuss some SUMO target genes that 
are involved in tumorigenesis. 
 
Androgen receptor (AR) is a critical transcription factor for prostate cancer 
development and progression (Balk and Knudsen, 2008) and has been identified as a 
SUMO target in which SUMOylation reduces hormone-induced transcriptional 
activity of AR (Poukka et al., 2000). DeSUMOylation of HDAC1 by SENP1 was 
found to enhance AR-dependent transcription via reduction of deacetylase activity in 
the transcription complex (Cheng et al., 2004). In accordance with this report, SENP1 
is overexpressed in human prostate cancers specimens (Cheng et al., 2006).  
 
The transcriptional activity of ER and PR has been shown to be regulated by 
SUMOylation. SUMOylation on ERα within the hinge region is critical for ERα-
dependent transcriptional activation (Sentis et al., 2005). On the contrary, PR 
SUMOylation represses its transcriptional activity (Daniel et al., 2007). The examples 
of AR, ER and PR suggest that in such nuclear hormone-receptor associated 
transcription machinery, post translational modifications may hold significant roles to 
the tight regulation of the activity of these receptor. Errors in this regulation may 
result in the induction of hyperproliferation of cells and thus contribute to cancer 
development and progression. 
 
SUMOylation is also involved in p53-mediated cellular processes such as senescence 
and DNA repair. The ectopic expression of PIASy induces premature senescence in 
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human primary fibroblasts, and its deficiency results in the delayed onset of Ras-
induced senescence in murine embryonic fibroblasts (Bischof and Dejean, 2007; 
Bischof et al., 2006). p53, itself, can be SUMOylated and studies had shown that it 
leads to its reduced activation (Gostissa et al., 1999; Muller et al., 2000). 
 
The final stage of cancer progression is metastasis, and although the role of 
SUMOylation in this process has not been widely studied, recent reports indicate 
strongly that SUMOylation plays critical roles in the expression of metastatic 
suppressor gene KAI1/CD82 and also in the regulation of TGF-β signaling (Kang et 
al., 2008; Kim et al., 2005).  
 
KAI1 is a member of tetraspanin family that suppresses tumor metastasis by 
inhibiting cancer cell mortality and invasiveness (Dong et al., 1995; Liu and Zhang, 
2006). While overexpression of KAI1 gene represses tumor metastasis in mouse 
models (Dong et al., 1996; Kim et al., 2005), its expression is significantly 
downregulated in a variety of clinically adanced cancers of the prostate, bladder, 
esophagus squamous cells and also the breast (Dong et al., 1996; Uchida et al., 1999; 
Yang et al., 2000; Yu et al., 1997). Studies revealed the role of Tip60, a 
transcriptional coactivator, who contribtes to KAI1 expression. In these studies, Tip60 
acts as an antagonist for β-catenin and in metastatic cancer cells, the β-catenin/reptin 
corepressor complex replaces Tip60 (Kim et al., 2005). SUMOylation of reptin then 
potentiates the association between reptin and HDAC1 and enhances the repressive 
function (Kim et al., 2006b). At the same time, SENP1 had been shown to modulate 




Tumor-derived TGF-β promotes tumor cell metastasis by inducing epithelial-
mesenchymal transition and angiogenesis (Leivonen and Kahari, 2007). TGF-β 
signals through serine/threonine kinase receptor complexes which includes type I 
(TβRI) and type II (TβRII) receptors. Kang and group identified TβR1 to be a SUMO 
target in 2008 (Kang et al., 2008). SUMOylation of TβRI requires the kinase 
activation of both TβRI and TβRII, and it enhances the affinity of TβRI kinase to 
Smad proteins, which are the cytoplasmic mediators in the TGF-β pathway. This 
resulted in a more efficient phosphorylation and activation of Smad2/3 in response to 
TGF-β (Kang et al., 2008). 
 
Collectively, SUMOylation appears to be able to enhance the metastatic potentials of 
malignant cells through the regulation of transcription in different pathways. Thus, it 
can be speculated that in the event of excessive SUMOylation, cells are more prone to 
gain metastatic ability to become malignant. Furthermore, given that there are 
increasing number of oncogenes and tumor suppressor genes that are elucidated to be 
able to undergo SUMOylation, uncovering biological importance of SUMO 
modification in different proteins will provide tremendous information to 










 1.6 The NF-κB pathway 
 
1.6.1 Canonical and Non-canonical NF-κB pathways 
NF-κB (Nuclear factor of κB) is a sequence-specific transcription factor that is known 
to be involved in the inflammatory and innate immune responses. The name was 
given because it was found in the nucleus bound to an enhancer element of the 
immunoglobulin kappa light chain gene in B cells. Initially thought to be a B-cell 
specific transcription factor, it was later shown to be present in every cell type and 
holds multiple important functions in living organisms (Hayden and Ghosh, 2004; 
Hoffmann and Baltimore, 2006). 
 
There are several pathways leading to the activation of NF-κB (Figure 5), of which 
the most well known and categorized is the canonical pathway, triggered by a wide 
array of stimuli including inflammatory cytokines, bacterial and viral products. The 
NF-κB dimer, consisting of p65 and p50, is kept inactivated in the cytoplasm by 
inhibitor of κB (IκB) proteins. Upon stimulation by microbial or viral infections, or 
exposure to pro-inflammatory cytokines, IκB kinase (IKK) complex is activated, 
phosphorylating the NF-κB-bound IκB. This action causes IκB to be targeted for 
ubiquitination and subsequent degrading, in the process liberating the NF-κB dimers. 
These free dimers then translocate into the nucleus and turn on transcription of NF-κB 
targeted genes. The canonical pathway plays a pivotal role in innate and adaptive 
immune responses and stress responses, and also embryonic development (Hayden 













The non-canonical pathway, on the other hand, is inducible by LPS, CD40 and 
lymphotoxin receptors, LMP1, which selectively activates the NF-κB-inducing kinase 
(NIK) and Ikk1, leading to the phosphorylation of p100. This results in ubiquitination 
and partial proteolytic processing of the 26S proteosome to give p52. p52 then 
dimerises with Rel-B to translocate into the nucleus for transcriptional activation of 
targeted genes. The non-canonical pathway plays an important role in B-cell 
maturation and the formation of secondary lymphoid tissues (Hoffmann and 
Baltimore, 2006; Weih and Caamano, 2003) 
 
 
1.6.2 Atypical NF-κB pathway by genotoxic stress 
In recent years, another NF-κB pathway, termed as the atypical pathway, was 
discovered. Activation of this pathway requires a stimulus such as genotoxic stress 
causing DNA damage in the nucleus. Upon DNA double-strand break formation, 
ataxia telangiectasia mutated (ATM) is rapidly phosphorylated and kicks start a 
cascade of phosphorylations of several key targets implicated in cell cycle control, 
DNA repair or stress responses (Li et al., 2001).  
 
NF-κB essential modulator (NEMO) or IKKγ usually exists in the cytoplasm in a 
complex with IKKα and IKKβ. All signals that are transduced, regardless via which 
pathway, have to go through NEMO. Hence, NEMO is known to be a 'master' 
regulatory protein, and that the loss of it will cause inability for NF-κB activation. 
Mutations in NEMO gene results in immunodeficiencies like incontinentia pigmenti 
and hypohidrotic ectodermal dysplasia (Hayden and Ghosh, 2004). Under genotoxic 
stress, free NEMO in the cytoplasm translocates into the nucleus, and undergoes a 
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series of post-translational modifications. Firstly, NEMO is SUMOylated specifically 
by SUMO1 but not SUMO2/3 at lysine residues 277 and 309 (Huang et al., 2003). 
This process is also independent of ATM (Huang et al., 2003) and requires PIASy as 
the major E3 ligase (Mabb et al., 2006). Though only a small fraction of the total 
NEMO pool undergoes this modification, mutations in the acceptor sites for these 
modifications completely block NF-κB activation by multiple genotoxic agents (Wu 
and Miyamoto, 2008). In contrast, these mutations of NEMO do not significantly 
perturb activation under the canonical pathway, suggesting the critical need for 
NEMO SUMOylation for NF-κB activation under genotoxic stress.  
 
After NEMO is SUMOylated, it is targeted for phosphorylation by ATM at serine 85 
and then subsequently targeted for monoubiquitination at the same lysine residues 
where SUMOylation occurs (Huang et al., 2003; Wu et al., 2006). 
Monoubiquitination of NEMO sets the trigger for its export out of the nucleus, back 
to the cytoplasm, where NEMO then reunites with IKKα and IKKβ to form the IKK 
complex, entering the canonical pathway to activate NF-κB. DeSUMOylation of 
NEMO occurs rapidly since SUMOylation is a reversible process and SENP2 has 
been recently identified to be the major deSUMOylating enzyme to do so (Lee et al., 
2011). Despite these, the functional significance of SUMOylation of NEMO in cancer 








1.6.3 NF-κB and Cancers 
Even though there are abundant findings over the years, the molecular mechanisms 
involved in the initiation and progression into metastasis of cancer are still largely 
unknown. It is due to the fact that cancers are commonly heterogeneous and are 
presented very differently clinically. As such, therapeutic strategies for treatment of 
cancers do not yield optimistic results. 
 
NF-κB activation participates in many levels of different pathways and its inhibition 
may lead to the suppression of cancer development. Constitutive or deregulated 
activation of NF-κB is found in many malignancies, including that of breast (Ghosh 
and Karin, 2002).  
 
p65 was found to be activated in the majority of human breast cancer cell lines and 
correlated with the conversion of breast cancer cells to hormone-independent growth 
(Nakshatri et al., 1997). Another study reported that antagonist to NF-κB blocked 
epidermal growth factor-induced NF-κB activation and caused apoptotic death in ER 
negative breast cancer cells (Biswas et al., 2000). On the other hand, it was 
demonstrated, in rats, that NF-κB activation is an early event, occurring before 
malignant transformation of the mammary tumors (Kim et al., 2000). This is a strong 
indication that the activation of NF-κB plays an early and critical role in the malignant 
transformation of mammary glands. The expression of p65 in human breast cancer 
was also examined. Several groups saw increased NF-κB activity in in vitro human 
cell lines, in vivo rat breast cancer and clinical biopsies, with significantly increased 
staining of p65 in the nuclear region. Additionally, several mRNA of NF-κB regulated 
47 
 
genes were also found to be elevated in breast tumors compared to their adjacent 
normal tissues (Cogswell et al., 2000; Sovak et al., 1997). 
 
Though the precise mechanisms of NF-κB activation in cancer progression are not 
known, it has been generally linked to be modulating the expression of many 
important genes involved in mammary carcinogenesis. NF-κB directly induces the 
expression of MMP9, chemokine receptor CXCR4 and urokinase-type plasminogen 
activator (uPA), thereby promoting extracellular matrix degradation and cancer cell 
migration (Helbig et al., 2003; Sliva et al., 2002). Therefore, constitutive activation of 
NF-κB in cancers would indicate that these genes are also upregulated. The NF-κB 
signaling system will therefore represent a critical intra-cellular pathway for breast 
cancer development and any drugs which are able to target this pathway should yield 
positive results. 
 
Having said that, thus far, many therapeutic strategies aiming to suppress the NF-κB 
activation are faced with a brick wall. Many tumors are found to be chemo-resistant to 
such drugs, very possibly due to the fact that increased NF-κB would also cause cells 
to be resistant to apoptosis, and thereby resisting chemotherapeutic drugs (Karin, 
2006; Pahl, 1999). However, inhibition of NF-κB will enhance the sensitivity of 
tumor cells to apoptosis induced by chemo-therapeutic agents. Some groups had 
demonstrated that the use of parthenolide, an NF-κB inhibitor, was able to increase 
the sensitivity of breast cancer cell to taxol treatment (Patel et al., 2000). Another 
group showed that using BAY11-7082, a pharmacological IκB inhibitor, had also 




There have been extensive reports of clinically available drugs that interfere with NF-
κB activity, either directly or indirectly. Statins, used clinically for the treatment of 
hypercholesterolemia, inhibit the rate-limiting enzyme of the mevalonate pathway 3-
hydroxy-3-methylglutaryl-CoA reductase which plays a central role in the production 
of cholesterol in the liver (Figure 6). Extensive studies over the years had 
demonstrated that statins exert pleiotropic effects like, pro-apoptotic, growth 
inhibitory and prodifferentiation responses on neoplastic cells of diverse origins 
(Denoyelle et al., 2001; Kang et al., 2009; Li and Brown, 2009; Menge et al., 2005).  
 
Furthermore, some had reported that statins are able to inhibit metastasis in cancers by 
interfering with NF-κB activation and downregulating NF-κB-regulated metastatic 
genes like MMP9 and CXCR4 (Aberg et al., 2008; Ghosh-Choudhury et al., 2010; 
Mannello and Tonti, 2009). Additionally, malignant cells appear to be highly 
dependent on the sustained availability of the end products of the mevalonate pathway 
and deregulated or elevated activity of HMG-CoA reductase had been shown in 
different tumors (Wong et al., 2002). Others reported high mRNA levels of HMG-
CoA reductase to be correlated with poor prognosis and that inhibitors of HMG-CoA 
reductase are able to reduce cancer incidence by 28-33% (Clendening et al., 2010). 
Despite so, the use of statins alone for anti-cancer therapy may require deeper analysis 
due to conflicting reports showing increased incidence of cancers (Gazzerro et al., 






Figure 6. Mevalonate pathway and site of Statins inhibition (Adapted from Menge 
et al., 2005). 
 
Taken together, adjuvant therapies using inhibitors of NF-κB pathway and 
chemotherapeutic drugs seem to be a very promising treatment for cancers. However, 
there remain concerns about the specificity of the NF-κB inhibitors as the activation 
of NF-κB also plays critical roles in several physiological processes. The inhibitors 
must be able to selectively target the diseased tissues or cells and keep toxicity to its 
minimum. Hence, more studies are required to elucidate the precise mechanism of 
action of different members in the NF-κB pathways and elucidate a therapeutic 





1.7 Scope of study 
Mortality from breast cancer is almost entirely the result of invasion and metastasis of 
neoplastic cells from the primary tumors to distant organ sites. Therefore, 
understanding the genes and gene products involved in breast cancer metastasis is an 
important research goal. As it is not possible to accurately predict the risk of 
metastasis development in individual patients, nowadays, more than 80% of patients 
receive adjuvant chemotherapy, but approximately 40% of them relapse and 
ultimately die of metastatic breast cancer. 
 
Therefore, new prognostic markers are urgently needed to identify patients who are at 
the highest risk for developing metastases. Furthermore, improving our understanding 
of the molecular mechanisms of the metastatic process might also improve clinical 
management of the disease.  
 
As discussed previously in Chapter 1.4, it suggests a possible association of DP103 to 
cancer metastasis. Hence, my project aims to first confirm and deduce the role of 
DP103 to breast cancer and cancer metastasis. We will also analyze the strength of 
DP103 as a prognostic marker for breast cancer metastasis. Upon establishing this 
potential association, we will then look further into the mechanism of how DP103 is 








CHAPTER 2  MATERIALS AND METHODS 
 
2.1 General buffer preparation 
 Phosphate buffered saline (PBS). 137mM NaCl, 2.7mM KCl, 4.3mM 
Na2HPO4, 1.4mM KH2PO4, pH 7.4 
 TE Buffer. 10mM Tris-HCl, 1mM EDTA, pH 8.0 
 
 Bacteria Transformation 
o LB broth. 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
0.5% (w/v) NaCl, pH 7.0 
o LB agar. 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
0.5% (w/v) NaCl, 2% (w/v) Bacto-agar 
 
 Agarose Gel Electrophoresis 
o 10X TBE. 0.89M Tris, 0.89M Boric Acid, 0.02M EDTA 
o 6X Sample Loading Buffer. 0.25% (w/v) Bromophenol blue, 0.25% 
(w/v) Xylene cyanol, 30% (v/v) glycerol 
 
 SDS-PAGE and Western Blotting 
o Tris, pH 8.8. 1.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 8.8 with 
concentrated HCl 
o Tris, pH 6.8. 0.5M Tris base, 0.4% (w/v) SDS, pH adjusted to 6.8 with 
concentrated HCl 
o 10X SDS-PAGE Running buffer. 0.25M Tris base, 1.92M Glycine, 
1% (w/v) SDS 
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o 1X Transfer buffer. 0.025M Tris base, 0.192M Glycine, 20% 
Methanol 
o Blocking buffer. 5% skim milk powder in 1X TBS-T 
o 1X TBS-T. 50 mM Tris.HCl, pH 7.4 and 150 mM NaCl, 0.1% Tween-
20 
o 5X Loading Dye. 0.25M, pH 6.8 Tris-HCl, 0.5M DTT, 0.25% 
Bromophenol blue, 50% glycerol, 10% SDS 
 
 SDS-PAGE gel 
o 10% Resolving gel 
 30% Acrylamide 3.3ml 
 1.5M Tris (pH 8.8) 2.5ml 
 10% SDS  0.1ml 
 10% APS  0.1ml 
 TEMED  0.004ml 
 dH2O   4.0ml 
o 5% Stacking gel 
 30% Acrylamide 0.5ml 
 1.0M Tris (pH 6.8) 0.38ml 
 10% SDS  0.03ml 
 10% APS  0.03ml 
 TEMED  0.003ml 





 Protein extraction 
o 1X RIPA buffer. 50mM Tris at pH 7.5, 150mM NaCl, 1% v/v NP-40, 
1% v/v deoxycholic acid, 0.1% v/v SDS and 1mM EDTA. 1mM 
PMSF, leupeptin, pepstatin A, aprotinin and Na3VO4 were added 
freshly before use 
 
 Measurement of Cell Viability 
o Crystal Violet Solution. 0.75% crystal violet, 50% ethanol, 1.75% 
formaldehyde, 0.25% NaCl 
o MTT Solution. 5mg/ml MTT dissolved in 1X PBS and filtered 
 
2.2 Cell lines and cell culture 
MCF-7, MDA-MB-231, HS578t and BT549 human breast cancer cells were grown in 
Roswell Park Memorial Institute (RPMI) 1640 medium supplemented with 10% fetal 
bovine serum (FBS), 2mM L-glutamine and 0.05mg/ml gentamicin (BioWhittaker). 
BT474 cells were grown in Dulbecco’s Modified Eagle’s Medium/F12 (DMEM/F12) 
medium with the same supplements as above. SKBr3 cells were grown in McCoy’s 
5A media with the same supplements as above. MCF10A and 184A1 cells were 
grown in Mammary Epithelial Growth Medium (MEGM, Clonetics, La Jolla, CA) 
supplemented with 10% FBS, 2mM L-glutamine, bovine pituitary extract and 
0.05mg/ml gentamicin. Xenograft-derived breast cancer cell lines (MCF10A1, 
MCF10AT1KCl.2, MCF10CA1h, and MCF10CA1aCl.1) were maintained in 
DMEM/F12 with 5% horse serum, 100U/ml Pen/Strep, 10µg/ml Insulin, 20ng/ml 
EGF (Millipore, Bedford, MA), 0.5µg/ml Hydrocortisone and 100ng/ml cholera 
toxin. All cell lines except xenograft-dervied were purchased from American Type 
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Culture Collection (ATCC, Manassas, VA), media and supplements from Hyclone 
(Logan, UT) unless otherwise indicated. Doxorubicin, VP16 (Etoposide) and 
Camptothecin were purchased from Calbiochem (La Jolla, CA). All other chemicals 
and reagents are from Sigma (St Louis, MO) unless otherwise indicated. Glutamine 
decomposes in culture medium in a time and temperature dependent manner. At 
37°C, glutamine’s half-life is eight days; at 4°C, its half-life is 40 days. Ammonia is 
the product of decomposition and it is potentially toxic. Hence, culture media need to 
be supplemented with glutamine. Gentamicin is an aminoglycoside antibiotic to 
control low levels of possible contamination. The cell lines were subcultured in 75cm
2
 
flasks (NUNC, NY, USA) every three days with a ratio of 1:3. For experiments, cells 
were resuspended from culture flasks using trypsin. Cells were then pelleted by 
centrifugation at 1300rpm and the supernatant removed. Cells were resuspended in 
media and counted using a haemocytometer before being seeded into six-well plates 
or 100mm tissue culture dish (Falcon, NJ, USA). The cells were then incubated for 
48h to allow for attachment before performing any transfection or drug treatment. 
 
2.3 Small-interferring RNA (siRNA) 
Two unique siRNAs targeting non-conserved coding regions of DP103 were 
purchased from Invitrogen (Stealth RNAi, Life Technologies, Grand Island, NY):  
#1: 5’- CCA GUG AUC CAA GUC UCA UAG CUU U-3’; 
#2: 5’- GCU GCC GCU UCU CAU UCA UAU UAU U-3’. 
They were tested for knockdown for DP103 and a combination of both siRNAs were 
used for all experiments subsequently as the reduction of DP103 was most significant 
(See Chapter 3.2). 5’-AGC UUC AUA AGG CGC AUG CTT (luciferase gene 
sequence inverted) was used as control siRNA (Qiagen, Valencia, CA). 
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2.4 Plasmid Constructs 
Full length-hFLAG-DP103 pcDNA3 was cloned from full length 2FLAG-hDP103, a 
kind gift from Dr Christopher Glass from Univeristy of California, San Diego and are 
used in Klappacher et al., 2002. Helicase-dead mutant 2FLAG-hDP103-GNT pcDNA 
was derived from 2FLAG-hDP103 pcDNA by PCR-mutagenesis (Stratagene, La 
Jolla, CA) using sense primer 5’-TCTGGTACCGGGAATACCTGTGTGTTC-3’ and 
antisense primer 5’-GAACACACAGGTATTCCCGGTACCAGA-3. The critical 
lysine residue needed to bind ATP (GKT) was mutated to an asparagines residue 
(GNT). Changing the conserved GKT to GNT has been shown to reduce ATP binding 
in RNA helicases by 98% (Richter et al., 1996). Flag-SENP2, HA-PIASy and Myc-
NEMO are kind gifts from Professor Shigeki Miyamoto from University of 
Wisconsin-Madison and are used in Mabb et al., 2006 and  Huang et al., 2003.  
For retroviral DP103 plasmid construction, a forward primer containing AgeI site and 
a reverse primer containing XhoI site was used to amplify the DP103 cDNA from Full 
length-hFLAG-DP103 pcDNA3. The amplified fragment was cloned into AgeI-XhoI 
cut pBobi plasmid, which contains a lentiviral backbone with the restriction sites 
placed immediately downstream of the Flag tag which is preceded by a CMV 
promoter. The primer sequences are: sense primer 5’-ATT 
AACCGGTATGGACTACAAGGAC-3’ and antisense primer 5’-
ATTACTCGAGTCACTGGTTACTATGCATC-3’. 
 
2.5 Virus preparation and infection 
pBobi-Flag-DP103 was co-transfected with pREV, pMDL and pVSVG plasmids into 
HEK293T cells at a ratio of 10:2.5:6.5:3.6 (in μg) per 10 cm dish. Virus containing 
media was collected at 48hrs and 72 hrs from a set of 4 transfected plates. The media 
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was then filtered and centrifuged at 23 000 rpm for 1.5 hrs. The virus pellet was 
resuspended in 800uL media and 50uL of concentrated virus used to infect cells in a 
6-well plate followed by expansion for experiments. 
 
2.6 Transfections 
For transient transfections, cells were plated at 2 x 10
5
 
cells per 6-well plate or 3 x 10
6
 
per 100mm dish 48h prior to transfection. Transfections were carried out using 
Lipofectamine RNAiMAX (Invitrogen, Life Technologies, Grand Island, NY) for 
siRNA according to the manufacturers’ instructions. The media was changed to 
DMEM supplemented with 10% FBS without any antibiotics 1h prior to transfection. 
Lipofectamine RNAiMAX and siRNAs (25nM of each oligomer, #1 and #2 were 
used to get a final concentration of 50nM) were separately diluted in Opti-MEM 
Reduced Serum Media (Invitrogen, Life Technologies, Grand Island, NY) for 5min 
before mixing together for another 20min of incubation at room temperature. The 
mixture was then added dropwise to the cells and returned to the 5% CO2 incubator 
for overnight transfection. After 18h, the media was removed, cells washed with 1X 
PBS and then supplemented with fresh complete media till day of harvest or drug 
treatment. For plasmid transfection, jetPRIME™ (Polyplus-transfection, Illkirch, 
France) was used. DNA was diluted in jetPRIME™ buffer first and jetPRIME™ 
reagent was then added. The mixture was vortexed briefly, incubated at room 
temperature for 10min before adding dropwise to the cells. They were returned to the 
5% CO2 incubator for overnight transfection. After 18h, the media was removed, cells 
washed with 1X PBS and then supplemented with fresh complete media till day of 




2.7 Protein isolation and concentration determination 
At time of harvest, cells were washed with ice-cold 1X PBS and harvested into a 
1.5ml eppendoff tube using a rubber policeman. Cells were then centrifuged to collect 
cell pellets. 1X RIPA lysis buffer, which is supplemented with Phenylmethylsulfonyl 
fluoride (PMSF, serine protease inhibitor), leupeptin (N-acetyl-L-leucyl-L-leucyl-L-
argininal, naturally occurring protease inhibitor for cysteine, serine and threonine 
peptidases), pepstatin A (aspartic proteases inhibitor) and aprotinin (serine protease 
inhibitor) were added to the pellets. 1mM of sodium orthovanadate (Na3VO4) acts as 
tyrosine phosphatase inhibitors. NP-40 serves as detergent used to solubilize the lipid 
in the cell membrane and other lipoproteins in the tissue. Deoxycholic acid also serves 
as detergent to solubilise fats. Sodium dodecyl sulphate (SDS) imposes a negative 
charge on solubilised proteins, thus aiding in protein migration during electrophoresis.  
Protein concentration determination of cell lysates was carried out using the 
Coomassie Dye (PIERCE, IL, USA) in a 96-well format. One microlitre of cell lysate 
was added to 200μl of Coomassie Dye and its absorbance at 595nm was read using a 
Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, Austria). The 
Coomassie Plus Protein Assay is based on an absorbance shift from 465nm to 595nm 
that occurs when the reagent binds to proteins in an acidic solution. The mechanism 
of the reaction is the anionic form of the dye complexes with proteins, resulting in a 
colour change from brown to blue. The dye interacts chiefly with arginine residues 
and weakly with histidine, lysine, tyrosine, tryptophan and phenylalanine residues. 
The reaction reaches a stable endpoint so the absorbance reading does not shift over 





2.8 SDS-PAGE and western blot analysis 
For detection of protein expressions, 30g of total protein per sample was incubated 
at 95°C for 10min before being subjected to SDS-PAGE (Polyacrylamide Gel 
Electrophoresis) at 80V for 20min followed by 125V for 1h using the BioRad Mini-
PROTEAN 3 Cell (CA, USA). Kaleidoscope prestained standards (BioRad, CA, 
USA) were also subjected to SDS-PAGE to facilitate the estimation of molecular 
sizes of the protein bands obtained. The resolved proteins were then transferred onto 
nitrocellulose transfer membrane by wet transfer method at 380mA for 1h 15min 
using the BioRad Mini Trans-Blot Electrophoretic Transfer Cell (CA, USA). After the 
transfer, the membrane was then blocked with 5% (w/v) fat-free milk in Tris-buffered 
saline/0.1% (v/v) Tween-20 (TBS-T) for 1h. Tween-20 is a mild detergent that 
reduces non-specific binding of antibody to lipid and protein. After three washes with 
TBS-T to remove excess milk, the membrane was incubated with the respective 
primary antibodies diluted in 5% BSA in TBS-T at 4°C overnight. The following day, 
the membrane was washed with TBS-T to remove unbound primary antibody, and 
then exposed to 1:10000 dilution of IgG-HRP-conjugated secondary antibodies in 5% 
(w/v) fat-free milk in TBS-T for one hour at room temperature. After three washes 
with TBS-T to remove unbound secondary antibodies, the probed proteins were then 
detected with Kodak Biomax MR X-ray film by enhanced chemiluminescent using 
SuperSignal Chemiluminescent Substrate (PIERCE, IL, USA). Human anti-mouse 
DP103 (1:1000 dilution) was purchased from BD Transduction Laboratories (San 
Diego, CA), human anti-rabbit MMP9 (1:1000 dilution), human anti-rabbit ICAM 
(1:1000 dilution), goat anti-mouse and goat anti-rabbit from Cell Signaling (Danvers, 
MA), human anti-rabbit NEMO (1:500 dilution), human anti-rabbit IKK2 (1:500 
dilution), human anti-mouse p65 (1:1000 dilution) from Santa Cruz (CA, USA) and 
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human anti-mouse SUMO-1 (1:2000 dilution) from Zymed (South San Francisco, 
CA). 
 
2.9 RNA isolation 
Total RNA was extracted using TRIzol® reagent according to the manufacturer's 
instructions (Invitrogen, Life Technologies, Grand Island, NY). Cells were scrapped 
in TRIzol® and transferred to 1.7ml eppendoff tubes. The homogenates were then 
stored for 5min at room temperature to permit complete dissociation of nucleoprotein 
complexes. They were then supplemented with chloroform, vortexed and centrifuged 
at 13 000rpm for 15min. Following centrifugation, the mixture separates into a lower 
red phenol-chloroform phase, interphase and an upper colourless aqueous phase. RNA 
remains exclusively in the aqueous layer whereas DNA and proteins are in the 
interphase and organic bottom phase respectively. The top colourless layer was then 
transferred into a fresh tube and equal volume of isoamyl alcohol/Chloroform (24:1) 
was added to reduce foaming and ensure deactivation of RNase. After centrifugation 
for another 15min, the top colourless layer was transferred to a new tube and equal 
volume of isopropanol was added and freezed in -80°C for at least half an hour. The 
samples were then thawed and spun down for 45min to precipitate the RNA. 
Precipitated RNA will form gel-like/white pellet at the side and bottom of the tube. 
The supernatant was then discarded and the pellet was washed with 75% ethanol. The 
samples were then centrifuged at 13000rpm for another 15min. Supernatant was then 
removed and RNA pellet was air-dried. The RNA was dissolved in ultra-pure water 
and concentration measured using NanoDrop® ND-1000 spectrophotometer 




2.10 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and 
Quantitative Realtime-PCR 
Each RT reaction contains 1µg of total RNA, 1X RT buffer, 5mM MgCl2, 425µM of 
each dNTPs, 2µM random hexamers, 0.35U/µl RNase inhibitor, 1.1U/µl 
MultiScribe™ reverse transcriptase and made up to 10µl with sterile water. RT 
reaction was carried out in PCR thermal cycle (Mastercycler gradient, Eppendorf, 
Hamburg) using the following steps. The reaction mix is heated at 25°C for 10min, 
followed by 37°C for 1h and finally at 95°C for 5min to terminate the reaction. A 
negative control for RT in which sterile water replaced the RNA template was 
included.  
Five microlitres of the 10µl cDNA reaction volume was used in quantitative 
Realtime-PCR using ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA) 
with 18S as an internal control (Applied Biosystems, Hs99999901_s1). Fluorescence 
was measured with the Sequence Detection Systems 2.0 software. Quantitative 
Realtime PCR was performed in multiplex (both target and endogenous control co-
amplified in the same reaction) with distinct fluorescent dyes. Primers and probes for 
various genes were purchased as kits from Applied Biosystems with their catalog 
numbers as follows: DP103: Hs 00200516_m1, CXCR4: Hs 00607978_s1. 
 
2.11 Immunoprecipitation 
For detection of endogenous protein interactions, whole cell lysate was prepared. A 
total of 3 x 10
6
 cells were treated as indicated and cell pellets lysed in lysis buffer. 
1mg of proteins were pre-cleared with magnetic G beads (Millipore, Bedford, MA) 
for 1h before rotating with 1μg of indicated antibody or normal mouse or rabbit IgG 
overnight at 4°C to preserve the proteins. Magnetic G beads were added the next day. 
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After 1½h of rotating, magnetic-enriched IP samples were washed four times in cold 
wash buffer (200mM Tris [pH 8.0], 100mM NaCl, 0.5% NP-40, 2mM DTT, 0.5mM 
PMSF, 1mM sodium orthovanadate, 1μg/ml leupeptin, 1μg/ml aprotinin). The 
samples were boiled in 5x SDS loading buffer, and proteins were separated by SDS-
PAGE. Proteins were then transferred to PVDF membranes and subjected to western 
blotting with the indicated antibodies. 
 
2.12 Wound healing assay 
MDA-MB-231 and BT549 cells were treated according to experimental design. 
Before plating the cells, two parallel lines were drawn at the underside of the well. 
These lines served as fiducial marks for the wound areas to be analysed. In 
preparation for marking the wound, the cells should be fully confluent. The growth 
medium was aspirated and replaced by calcium-free PBS to prevent killing of cells at 
the edge of the wound by exposure to high calcium concentrations. Two parallel 
scratch wounds were made perpendicular to the marker lines with a 1000µl blue tip. 
The medium was then changed to complete media. After incubation for 48h, the 
wounds are observed using bright field microscopy and multiple images were taken at 
areas flanking the intersections of the wound and the marker lines at the start and end 
of the experiment. Three measurements of the gap distance between the wound were 
taken at the start and end of the experiment from the images, and their averages are 
converted to percentages to depict percentage change with the control setup taken to 






2.13 2D migrational assay 
Glass cylinders (Bioptechs, Butler, PA) of 6 mm inner diameter were placed vertically 
on tissue culture dish. About 20 000 cells were seeded inside the glass cylinders and 
incubated at 37°C in a humidified atmosphere at 5% CO2 for 24 hours. The cylinders 
were then carefully lifted from the dish to reveal an undisturbed circular monolayer 
patch of cells, which were then washed thrice with 1X PBS to remove dead cell debris 
and refilled with 2ml of complete medium. Live video monitoring assays of the 
migrating cells at the edge of the monolayer were performed using phase contrast 
microscopy (Biostation IM, Nikon). Rectangular fields of view with pixel resolution 
1280 x 960 (microscope objective of 10x magnification) were chosen from the 
monolayer edge using the proprietary software and videos were recorded for 24h with 
10min intervals in between the frames (total 145 frames). Fifty cells from 6-8 rows of 
the leading edge of the monolayer were manually tracked using the open source 
software Image J. Monolayer edge distances (MED) were measured as the average of 
the displacements (n=5 per field of view measured for 4-5 videos per experiment) 
between the initial and final positions of the monolayer edge. 2D track plots and plot 
related measurements were performed using the Chemotaxis tool plugin (Integrated 
BioDiagnostics) for Image J. The following are the definitions used to estimate the 
cell migration parameters: 
- Accumulated Distance (AD) – The total distance traversed by individual cells 
as estimated by measuring the length of the cell tracks. 
- Euclidean Distance (ED) – The displacement between the initial and the final 
positions of individual cells as estimated by the distance between the starting 
and ending position of the cell tracks. 
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- Mean Cell Speed – The average speed of migration of all the tracked cells 
during the 24 hour duration. The speed of individual cells is measured as the 
ratio of the accumulated distance to the total time period of observation.  
- Confinement Ratio – A ratio between the Euclidean distance and the 
Accumulated distance that is used as an indicator of the straightness of the cell 
migration tracks. A value of 1 indicates an absolutely straight path while 
values towards 0 indicate tortuous paths.  
- Center of mass (CM): Center of mass of the coordinates of all endpoints (final 
positions) of the cell tracks. 
        x = .   
        y =  .  
where x and y represent the coordinates of the endpoints of a particular cell 
track. 
        -  
where CM Length represents the distance from the origin to the center of 
mass. 
 
2.14 In vitro and 3D invasion assay 
 In vitro invasion assay was performed using BD Bio-Coat Matrigel invasion assay 
system (BD Biosciences, San Jose, CA) according to the manufacturer’s instructions. 
Briefly, cells were trypsinized 48h post-transfection, 2 x 10
5 
cells suspended in serum-
free medium and seeded into the Matrigel transwell chambers consisting of 
polycarbonate membranes with 8-μm pores. Regular medium containing 10% FBS 
was added to the bottom chamber to act as chemoattractant. After incubation for 24h, 
the media in the transwell chamber was removed, and upper surface of the chambers 
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was wiped off with a cotton swab. The invading cells were fixed and stained with 
crystal violet solution. The invading cell numbers were counted in five randomly 
selected microscope fields (200) and their averages were converted to percentage 
with the control setup taken to be at 100%.  
For 3D invasion assay, Nutragen
TM
 collagen solution (Inamed Biomaterials, Fremont, 
CA, US) was mixed with NaOH, 10X PBS, and MDA-MB-231-GFP cells suspended 
in serum-free DMEM on ice. The final solution contained 4mg/ml of collagen-I and 
200 000/ml cells. After 30 to 60min of incubation under 37°C humidified chamber, 
self-assembly of a piece of semi-spherical cell-seeded collagen gel in the central well 
of a glass-bottomed dish was formed. Complete cell culture media were immediately 
supplied to the gel to support cell growth. After 40h, these GFP-expressing cells were 
imaged in 3D collagen hydrogel using confocal fluorescence microscopy (Nikon 
TE2000-EZ C1 system). Ten hours of time-lapsed confocal imaging was then carried 
out in an environment chamber maintaining 37°C and 5% CO2 atmosphere, which 
was completed within 70 hours post siRNA transfection. Quantitative image analysis 
was achieved using 3D reconstruction and cell tracking function provided by Imaris 
(Bitplane, Zurich, Switzerland). 
 
2.15 Electrophoretic mobility shift assay 
The EMSA technique is based on the observation that protein:DNA complexes 
migrate more slowly than free DNA molecules when subjected to non-denaturing 
polyacrylamide or agarose gel electrophoresis. Cell pellets were lysed in lysis buffer 
(50mM KCl, 0.5% IGEPAL CA-630, 25mM HEPES pH 7.8, 10μg/ml leupeptin, 
20μg/ml Aprotinin, 125mM DTT, 1mM PMSF) and kept on ice to break the cell 
membrane. They were then spun down and supernatant was removed as cytoplasmic 
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extract. The nuclear pellet was washed with washing buffer (50mM KCl, 25mM 
HEPES pH 7.8, 10μg/ml leupeptin, 20μg/ml Aprotinin, 125mM DTT, 1mM PMSF) 
before resuspending it in extraction buffer (50mM KCl, 25mM HEPES pH 7.8, 10% 
glycerol, 10μg/ml leupeptin, 20μg/ml Aprotinin, 125mM DTT, 1mM PMSF). The 
pellet was then freezed at -70°C for at least half an hour, before thawing and 
centrifugation. The supernatant collected was the nuclear extract. The same sample 
was divided into 2 separate samples for analysis with double-stranded NF-κB, AP-1 
and Oct-1 [γ-32P] radiolabeled probes.  
NF- κB: 5’-TCA ACA GAG GGG ACT TTC CGA GAG GCC-3’ (designed by us) 
AP-1: 5′- CGC TTG ATG ACT CAG CGG GAA-3′ (Lukiw et al., 1998) 
Oct-1: 5’- TGT CGA ATG CAA ATC ACT AGA A-3’ (Feng and Williams, 2003) 
The DNA probe was labeled radiolabeled by incubation at 37C for 30min with the 
following: 5x forwarding buffer, 
32
P-γ-ATP and T4 kinase (10 unit/μl). The labeled 
probe was then spun at 3000 rpm for 1 min to get rid of the buffer, followed by 
loading into the G50 micro column (Pharmacia Biotech, UK) and spun for 2 min for 
purification. EMSA was performed in a reaction mixture containing 2x reaction buffer 
(50% glycerol, 1M Hepes pH 7.9, 1M Tris-HCl pH 8.0, 0.5M EDTA pH 8.0, 100mM 
DTT), 0.5μg/μl poly (dI-dC), protein samples and 1μg/μl BSA and kept on ice for 
10min before adding DNA probes. The mixture was then kept at room temperature for 
another 20min before loading into a non-denaturing polyacrylamide gel and run for 
1h. The gel was then dried and analyzed with a PharosFX Plus system (BioRad, 






2.16 Gel zymography 
Gelatinolytic enzymes secreted by cultured cells were identified and quantified by 
electrophoresis of serum-free conditioned medium in gelatin-embedded 
polyacrylamide gel. Cells were treated according to experimental setup and finally 
cultured in serum-free media for 24h. At time of harvest, the medium was collected 
and the non-concentrated supernatants were concentrated using Vivaspin® 
concentrators (Vivascience, Stonehouse, UK). The concentrates were then mixed with 
SDS sample buffer without DTT (reducing agent). Electrophoresis was carried out on 
10% denaturing polyacrylamide gels containing 10% gelatin. Following 
electrophoresis, the gels were rinsed twice with 50mM Tris-HCl buffer (pH 7.5) 
containing 2.5% Triton X-100 for 15min each time, and incubated at 37°C for 16h in 
a buffer composed of 0.15M NaCl, 10mM CaCl2 and 50mM Tris-HCl (pH 7.5). The 
gels were stained with 0.05% Coomassie blue in 10% ethanol and 10% acetic acid, 
and destained with 10% ethanol and 10% acetic acid. Media collected from MCF10A 
cells treated with various concentrations of TNF-α were used as a reference as MMP9 
activity increases upon such stimulation (Stuelten et al., 2005). 
 
2.17 Luciferase assay 
MDA-MB-231 and BT549 (1.25 x 10
5
 cells/well) were plated in 12-well plates. 
Experiments were set up as described. Cells were seeded for 48h prior to transfection. 
Cells were transfected with siRNA against DP103 described above. After 24h, the 
cells were then transfected with luciferase reporter plasmid containing 3x NF-κB or 
AP-1 binding sites together with Renilla plasmid (Clonetech, Palo Alto, CA). Renilla 
transfection was used to check for transfection efficiency. At time of harvest, the 
promoter activity was assessed with a dual-luciferase assay kit (Promega, Madison, 
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WI). Feeding medium was removed from the wells, washed once with 1x PBS, and 
lysed with ice-cold 100l of reporter lysis buffer. Ten microlitres of cell lysate was 
then added to 50l of luciferase substrate solution, following which 50l of stop & 
glow buffer was added for Renilla reading. Bioluminescence generated was measured 
using a Sirius luminometer (Berthold Technologies, Herefordshire, UK). The 
luminescence readings obtained were normalized to the protein concentration of the 
corresponding cell lysate and presented as fold difference with reference to the control 
setup. 
 
2.18 Measurement of cell viability via crystal violet and 3-(4, 5-Dimethylthiazol-
2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay 
Cell growth/cytotoxicity was assessed by determining the number of intact cells over 
time using the crystal violet uptake assay. At the end of drug treatment or transfection, 
medium was removed from the wells. The cells were then washed once with 1X PBS. 
This was followed by incubation with 0.5ml of crystal violet solution for ten minutes. 
Excess crystal violet solution was carefully washed away with distilled water for 
several times and the wells were left to air-dry. The remaining crystals were dissolved 
in a 1% SDS in 1X PBS solution and its absorbance read at 595nm using the 
Spectrofluoro Plus spectrophotometer (TECAN, GmbH, Grödig, Austria). The 
amount of dye released reflects the quantity of intact cells present in each well. 
Another assay that was used to assess cell viability is MTT. Similar to crystal violet 
assay, MTT is also a functional assay. Similar experimental set up was performed. 
MTT assay is based on the ability of mitochondrial dehydrogenase enzyme from 
viable cells to cleave the tetrazolium rings of the pale yellow MTT and form dark blue 
formazan crystals which is largely impermeable to cell membranes, thus resulting in 
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its accumulation within healthy cells. Three hours before the end of treatment, MTT 
solution was added into each well containing cells at 1:10 dilution. The cells were 
then incubated at 37°C with 5% CO2. Three hours after the incubation, the medium 
was removed carefully with a pipette tip and DMSO was added to each well to 
solubilise the crystals. The number of surviving cells is directly proportional to the 
level of formazan product formed. The quantity of formazan present was determined 
by measuring its absorbance at 550nm using the Spectrofluoro Plus 
spectrophotometer (TECAN, GmbH, Grödig, Austria). 
 
2.19 Clinicopathological data  
The study cohort consisted of 98 breast cancer cases (invasive ductal 
carcinomas representing all grades and stages) treated by surgical resection at the 
National University Hospital of Singapore. The median age of patients was 52 years 
(range 29–86). The distribution of patients according to the three most common ethnic 
groups in Singapore showed that they were of Chinese (81%), Malay (15%) or Indian 
(4%) descent. Histopathological staging was based on the TNM staging system and 
grading of tumors. This work was approved by the ethics committee of the National 
University of Singapore (DSRB Domain B/09/284).  
Another cohort of a total of 48 primary breast cancer and 15 benign breast tissue 
samples derived from 63 patients who underwent surgery at the First Affiliated 
Hospital of Anhui Medical University (Hefei, Anhui, People’s Republic of China) 
between 2009 and 2010 was obtained. All tissue samples were hematoxylin and eosin 
stained and had been reviewed by two independent pathologists in Anhui Medical 
University. Total RNA from these breast tumor tissue samples was extracted by 
TRIzol® (Invitrogen, Life Technologies, Grand Island, NY), reversely transcribed 
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into cDNA by using RevertAid First Strand cDNA Synthesis Kit (K1622, Fermentas, 
Germany) and Real-time PCR was carried out by using SYBR Premix Ex Taq 
(DRR041A, TaKaRa, Shiga, Japan) in a Stratagene MX3000P detection system 
(Stratagene, La Jolla, CA, USA). Primer sequences used for qPCR expression in 
patient tissues from First Affiliated Hospital of Anhui Medical University are DP103-
F: 5'-TGCCAGTAAACAGATGC-3', DP103-R: 5’-GTGCCAAAGGGTATGA-3'; 






Formalin-fixed, paraffin-embedded tissue was cut into 5 μm section, de-paraffinized 
in xylene, rehydrated through graded ethanol, quenched for endogenous peroxidase 
activity in 3% (v/v) hydrogen peroxide, and processed for antigen retrieval by heating 
in 10 mM citrate buffer (pH 6.0) at 90-100°C. Sections were incubated at 4°C 
overnight with DP103 antibody from Santa Cruz (CA, USA) and MMP9 antibody 
from Cell Signaling (Danvers, MA) in 1:100 dilution. 
 
2.21 Tissue microarray construction 
Tissue microarray (TMA) blocks containing cores from 98 breast cancer patients were 
constructed as described previously (Das et al., 2008; Salto-Tellez et al., 2007).  
Briefly, a needle with 0.6 mm diameter was used to punch a donor core from 
morphologically representative areas of a donor tissue block. The core was 
subsequently inserted into a recipient paraffin block using an ATA-100 tissue arrayer 
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(Chemicon, USA). Three cores were taken from the center of tumor tissue and a 
single core was taken from histologically-normal colon epithelium of matched cases. 
Consecutive tissue microarray sections of 4µm thickness were cut and placed on 
slides for immunohistochemical analyses by pathologists A/Prof Manuel Salto-Tellez 
(CSI, NUH) and Dr Thomas Choudary Putti (Pathology, NUH). The expression status 
of MMP9 and DP103 is scored by immunohistochemistry following standard 4-tiered 
scoring practice, ranging from 0 to +3. For statistical analyses (by biostatistican Mr 
Ong Chee Wee, CSI), negative (0) and weak expression (+1) were grouped together 
and termed as ‘negative expression’ of the proteins. Moderate (+2) and strong (+3) 
expression was termed as ‘positive expression’. McNemar's test was used for the 
analysis of scorings. Survival duration was measured from date of diagnosis till date 
of cancer-specific death, and censored for surviving cases. Survival curves were 
plotted using the Kaplan-Meier method and compared using the log-rank test. 
Student’s t tests were performed using the software Origin Pro and results are 
represented as mean ± standard deviation.  
 
2.22 Treatment of cells with Drugs 
Simvastatin and Lovastatin were purchased from Merck (San Diego, CA, USA) in 
sodium salt form. A stock solution of 60mM was prepared by diluting the powder in 
calculated amount of DMSO, depending on the molecular weight of the compound 
and then stored in -20°C freezer. Various concentrations of the statins were then 
prepared by diluting the stock solution with complete medium to attain the indicated 
final concentrations. 
Specific MMP9 Inhibitor I, Broad spectrum MMP inhibitor (GM6001) and specific 
MMP2/9 inhibitor (SB-3CT) were purchased from Calbiochem (La Jolla, CA). They 
71 
 
were dissolved in DMSO and stored at -80°C freezer. Various concentrations of the 
statins were then prepared by diluting the stock solution with complete medium to 
attain the indicated final concentrations. 
 
2.23 Metastatic qPCR Array and microarray 
Total RNA was extracted and reverse transcription was carried out as described 
above. The relative expressions of various genes were then analyzed using 
quantitative RT-PCR (ABI PRISM 7900, Applied Biosystems, Foster City, CA, 
USA). Multiple gene markers distributed around the genome and three housekeeping 
genes were used for real-time PCR analysis using the SYBR GreenER qPCR 
SuperMix for ABI PRISM (Invitrogen, Life Technologies, Grand Island, NY). 
Triplicate reactions were performed for each marker in a 384-well plate using a two-
step amplification program of initial denaturation at 95°C for 10 min, followed by 40 
cycles of 95°C for 20 sec and 60°C for 30 sec. A melting curve analysis step was 
carried out at the end of the amplification, consisting of denaturation at 95°C for 1 
min and reannealing at 55°C for 1 min. Sequences of primers used are as described 
previously (Pandey et al., 2010; Qian et al., 2011) and can be found in Appendix 1. 
DP103 expression levels were analyzed in breast tumors using a multi-institutional 
“microarray meta-cohort” totaling 759 primary breast cancer cases. The normalized 
microarray data set and associated clinical annotations are described in Miller et al., 
2011 and can be downloaded at https://sites.google.com/site/millerirgs/ as 
supplemental data files 1 and 2 (Miller et al., 2011). Briefly, all tumor samples were 
analyzed from frozen tissue collected at surgery and profiled on an Affymetrix U133 
series microarray according to standard Affymetrix protocols. Raw data (ie, CEL 
files) were normalized by Robust Multichip Average (RMA) using the Bioconductor 
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“Affy Package (R)” as previously described (Irizarry et al., 2003). Batch effects 
between cohorts were corrected using the Partek Genomics Suite Batch Remover 
program. Differential expression of DP103 between breast cancer subgroups was 
assessed by Mann–Whitney U test and Student’s t-test. 
 
2.24 In vitro SUMOylation assay 
SENP2 and PIASy were prepared by IP with anti-HA antibody from HEK293 cells 
transfected with HA-tagged SENP2 or PIASy constructs. His-DP103 was bacterial 
recombinant protein purified from pSY5-His-DP103. NEMO protein was produced 
using wheat germ lysates by in vitro TNT reaction with TNT® Quick Coupled 
Transcription/Translation System kit (Promega, Madison, WI). In vitro SUMOylation 
was performed by preparing a reaction mix containing 1mg/ml recombinant SUMO-1, 
1unit/μl SUMO E1 and 0.4mg/ml Ubc9 proteins, and incubating at 37°C for 2h as in 
Mabb et al., 2006. After 2h, the mixture was incubated for 3min at 95°C before being 
resolved using 12% polyacrylamide gels and immunoblotted with different antibodies. 
 
2.25 In vivo mouse model 
The sodium salt of Simvastatin was used for this study. Simvastatin was sonicated 
into suspension in saline for animal experiments. To ensure that toxicity would not be 
a factor, we conducted a preliminary dosage-tolerance study for the proposed 0 
(saline), 25 and 50mg/kg dosages of Simvastatin using 4 mice for each dose, similar 
to our previous studies (Shibata et al., 2004). The animals were injected intra-
peritoneal (i.p.) with the appropriate dose 3 times a week for 9 consecutive weeks. No 
deaths occurred in any of the groups and only the 50mg/kg group showed a 10% 
weight loss at week 9 compared with controls, indicating that no dose adjustments 
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were necessary. To avoid any confounders in our setup, we chose the feeding dose of 
Simvastatin to be 25mg/kg. 
MDA-MB-231 cells (1 x 10
6
 cells suspended in 200μl PBS) were inoculated i.p. into 
the tail vein of sixteen female nude mice. Two weeks later, when tumors had 
developed to about 0.2cm in diameter, groups of eight mice each were injected i.p. 
with either vehicle alone or with 25mg/kg Simvastatin three times a week for six 
weeks. At the end of the six weeks, the mice were killed with diethyl ether and 
exsanguinated. 
At necropsy tumors and lymph nodes, routinely those from the axillary and femoral 
regions as well as those appearing abnormal, were removed, fixed in 4% 
formaldehyde solution in phosphate buffer and processed through to paraffin 
embedding. Lungs were inflated with the formaldehyde solution prior to excision and 
immersion in fixative. The individual lobes were subsequently removed from the 
bronchial tree, trimmed into seven pieces and examined for metastatic foci before 
being similarly processed to paraffin embedding. All paraffin-embedded tissues were 
cut at 4 µm, with sequential sections stained with hematoxylin and eosin (H&E) for 
histopathological examination and reserved unstained for immunohistochemistry. 
 
2.26 Statistical Analysis 
Statistical analyses for other experiments not mentioned previously were performed 
using the SPSS package (version 15.0 for Windows, SPSS Inc., USA). The Student's 






CHAPTER 3  RESULTS 
 
3.1 DP103 expression in breast tissues: Is there any correlation between DP103 
levels and the state of malignancy? 
 
3.1.1 Expression of DP103 in different breast tissue malignancies 
Before the work done for this thesis, the expression of DP103 in breast malignancies 
was unreported. We retrieved a total of 194 breast tissue samples (97 breast cancers 
and 97 paired normal breast tissue) from the archives of the Department of Pathology, 
National University Hospital, Singapore and constructed a tissue microarray. Out of 
the 194 tissue samples, only 43 pairs of breast cancer and its paired normal breast 
tissue were successfully stained to make comparison. Staining was defined as 
immunostaining of cytoplasm above background level and scored as follows: (1+) 
representing weak expression; (2+) representing moderate expression; and (3+) 
representing strong expression. The absence of cytoplasmic staining was reported as 
negative (0). Table 2 shows the numbers of patients in each individual score. We used 
the cut-off value for negative or positive expression of DP103 to be 0 and 1+ versus 
2+ and 3+ respectively and pooled the scores in Figure 7. A significant number of 
patients had high expression of DP103 in their tumor and low expression of DP103 in 
their matched normal tissue as compared to other combinations (p<0.001). Two 
pictures representing the immunohistochemical staining of high DP103 in invasive 







DP103 Expression (Tumor) 
Total 




0 1 2 3 4 
10 
(23%) 
1+ 1 3 7 11 
22 
(51%) 
2+ 0 1 0 7 8 (19%) 
3+ 0 0 0 3 3 (7%) 
Total 2 (5%) 6 (14%) 10 (23%) 25 (58%) 43 
McNemar P<0.001 
 
Table 2. Number of cases screened for DP103 protein expression in human 







Figure 7. Graph showing number of cases screened for DP103 protein expression 
in human patient breast tumor and paired normal breast tissues, sorted 














Figure 8. Two representatives of tissue microarray showing higher DP103 
staining in invasive breast ductal carcinoma (left) and low staining in matched 





3.1.2 Expression of DP103 in breast cell lines 
To confirm the observation that DP103 is highly expressed in invasive breast cells 
and low in normal breast cells, a panel of breast cell lines, comprising of human 
normal breast epithelial, poorly invasive breast adenocarcinomas and highly invasive 
breast adenocarcinoma (Table 3) was analyzed for basal mRNA and protein levels of 
DP103. Figure 9 shows that both the mRNA and protein expression of DP103 are the 
highest in MDA-MB-231 and BT549, both which are highly invasive in nature, 
relatively lower levels in poorly invasive MCF7 and BT474, and having the lowest 
expressions in human breast normal epithelial MCF10A, 184A1 and poorly invasive 







Cell lines Tumor Type Tumorigenicity 
MCF7 Poorly invasive adenocarcinoma Yes 
BT474 Poorly invasive adenocarcinoma Yes 
MCF10A Normal non-tumor epithelial No 
MDA-MB-231 Highly invasive adenocarcinoma Yes 
BT549 Highly invasive adenocarcinoma Yes 
SKBr3 Poorly invasive adenocarcinoma Yes 
184A1 Normal non-tumor epithelial No 
 

























Figure 9. DP103 expression in a panel of breast cell lines. RNA of different breast 
cell lines were extracted and qPCR were performed with DP103 primer, normalized 
with 18S and represented as fold difference (A). Cells of different breast cell lines 









3.1.3 Expression of DP103 in isogenic xenograft-derived MCF10AT series cell 
lines  
Since the cell lines used in Figure 9 are all derived from different sources, the 
relationship between the increased expressions of DP103 with the degree of 
invasiveness cannot be established. Hence, we determined basal DP103 expression in 
an isogenic xenograft-derived MCF10 breast cancer progression model system. The 
MCF10 breast cancer progression model system was originally derived from Fred 
Miller’s laboratory (Choong et al., 2010; Choong et al., 2011; Dawson et al., 1996). 
Immortalized breast epithelial cell line MCF10A (10A1) was transfected with T24 c-
Ras oncogene and injected into nude mice. By reestablishing cells in tissue culture 
from one of the carcinomas, a cell line designated MCF10AT1 was derived that forms 
simple ducts when transplanted in Matrigel into immunodeficient mice. With time in 
vivo, the epithelium becomes proliferative and a cribriform pattern develops within 
the xenografts. A significant number progress to lesions resembling atypical 
hyperplasia and carcinoma in situ in women, and some progress to invasive 
carcinomas. Pre-malignant MCF10AT (AT1k), low grade MCF10CA1h (CA1h), and 
high grade MCF10CA1a (CA1a) cell lines were generated by reestablishing cells in 
tissue culture from these lesions representing successive transplant generations 
(Figure 10). With each generation, cells are somewhat more likely to progress to high 
risk lesions resembling the human proliferative breast disease. 
 
High grade CA1a cells were previously characterized to metastasize following 
orthotopic mammary fat pad and intravenous tail vein injections while 10A1 and 
AT1k cells failed to form tumors (Hurst et al., 2009; Santner et al., 2001; Worsham et 
al., 2006). As shown in Figure 11, basal levels of DP103, both at mRNA and protein 
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levels directly correlated with increasing invasive potential of these cell lines, with the 
lowest level of DP103 being observed in the normal 10A1 cells and highest 
expression being observed in the highly metastatic CA1a cells. The importance of this 
finding is that DP103 expression increases with the progression of breast cancer, 





















Figure 11. RNA and protein expression of DP103 from four isogenic cell lines. 
RNA were extracted and qPCR were performed with DP103 primer, normalized with 
18S and represented as fold difference (A). Total cell lysates were harvested, lysed for 
protein and western blotting was performed using DP103 antibody. The densitometry 



















3.1.4 Expression of DP103 in human cancer patients 
To determine if the same trend is also observed clinically, we obtained a total of 48 
primary breast cancer and 15 benign breast tissue samples derived from patients who 
underwent surgery from our collaborator Dr Zhu Tao from Hefei National Laboratory 
for Physical Sciences at Microscale and School of Life Sciences, University of 
Science and Technology of China, Hefei, Anhui, P.R. China. 
 
RNA was extracted from each of these patient samples and DP103 expression was 
examined. Patients whose breast cancer had metastasized showed upregulated 
expression of DP103 in the primary tumor when compared to breast cancer patients 
who did not show tumor metastasis. The tissues of patients with benign breast 
diseases were used to act as a control and DP103 expression was observed to be the 
lowest (Figure 12).  
 
Together with the results from the xenograft-derived cell lines, we showed, for the 
first time, the strong association of DP103 with the differential stages of cancer from 
normal epithelial to the high grade lesions. It is also the first time that DP103 is 
reported to be correlative to cancer progression, with its highest expression to be 





Figure 12. DP103 expression in human breast benign, non-metastatic (Non-Met) 
and metastatic (Met) tissues. Human patient samples were collected, RNA extracted 

































3.2 Effects of down-regulation of DP103 
Since DP103 has been shown to possess a correlation in its expression to the state of 
malignancy in breast cancer as well as its high expression in highly metastatic cell 
lines, it was hypothesized that down-regulation of DP103 in invasive breast cancer 
would decrease the invasive ability of the cells. Hence, two highly invasive breast 
cancer cell lines, MDA-MB-231 and BT549 were used in subsequent experiments.  
 
Before performing any functional assay, validation of the efficiency of the 
knockdown of DP103 using RNAi technology was done. Two unique siRNAs against 
DP103 (Figure 13) were first tested individually or pooled together for their 
efficiency. The advantage of using pooled siRNAs is increasing on-target effect while 
reducing the off-target effects. Within a complex mixture, each siRNA is at a lower 
concentration used for individual setup. However, the on-target effect of multiple 
siRNAs is additive. Although each siRNA may also have an off-target effect, it is 
noted that it will be different for each siRNA in the mix and therefore, the off-target 
effects will be diluted out (Nathan, 2008). 
 
In Figure 14, it was shown that the use of siDP103 #1 and #2 pooled together 
produced a better knockdown of DP103 as compared to them being used individually. 
Hence, this pooled mixture of siRNAs was used for all subsequent knockdown 
experiments and was labeled as ‘siDP103’ in this project. Furthermore, this 
knockdown of DP103 is effective transcriptionally and translationally in both MDA-




Figure 13. A pictorial representation of siRNA specific sites targeted at DP103 
(modified from Ou et al., 2001). 
 
 
Figure 14. Pooled siRNA against DP103 showed better knockdown. MDA-MB-
231 cells were transfected with various siRNAs either individually or pooled and then 










Figure 15. Validation of knockdown of DP103 in MDA-MB-231 and BT549. Cells 
were transfected with 2 unique siRNA against DP103 pooled together and then 
harvested for RNA and protein respectively at the times indicated. Realtime-PCR was 
performed with DP103 primer, normalized with 18S and represented as fold 
difference (A). Western blotting was performed using DP103 antibody. The 
densitometry values (indicated below the respective blots) were normalized with 











3.2.1 Knockdown of DP103 on cell viability 
Tumor formation stems from the inability to regulate cell cycle, causing erratic and 
uncontrollable cell growth. Cancer cells have to overcome several checkpoints in 
order to proliferate. Limitless replicative potential and evasion of apoptosis are two 
hallmarks of cancers (Hanahan and Weinberg, 2011) and since DP103 expression 
increases with the extent of tumor progression, we would like to ask if DP103 plays a 
role in the aberrant growth of breast cancer cells. 
 
To check for cell viability, MTT assay was performed and the suppression of DP103 
did not affect the viability in both MDA-MB-231 and BT549 cells at 24h and 48h 
(Figure 16). Importantly, this means that any changes seen in subsequent assays can 
be attributed to the decrease in DP103 expression after knockdown, and not due to the 
differences in the viability of the breast cancer cells. At the same time, our data also 
suggest that DP103 does not have any effect on short term cell viability of the cells, 
though more experiments will be needed to determine if it has any role in cell cycle, 





Figure 16. Cell viability is not affected when DP103 is knocked down. MDA-MB-
231 (A) and BT549 cells (B) were seeded into 12-well plates and transfected with 
either control siRNA or siRNA against DP103. MTT solution was added and 
absorbance read at 550nm to measure cell viability. The percentage of cell viability 











3.2.2 Knockdown of DP103 on cell migration using wound healing assay 
We next investigated the effect of DP103 down-regulation on cell migration using the 
wound healing assay. This method is one of the earliest developed to study directional 
cell migration in an in vitro model. It mimics cell migration during wound healing in 
vivo. By physically creating an artificial ‘wound’ in a cell monolayer, capturing and 
comparing images at the beginning and at the end of the assay, the migration rate of 
the cells can be quantified (Amin et al., 2003; Fahmy et al., 2003).  
 
As shown in Figure 17A, there was a marked decrease in the number of cells 
migrating into the wound in both MDA-MB-231 and BT549 cells after 48h. The 
difference in the gap distance of the wound at the start and the end of the assay would 
indicate the perpendicular distance that the cells move. The distances measured after 
48h were subtracted from the original length of the wound at the start of the assay. 
Subsequently, these measurements were converted to percentages showing migration 
distance as compared to the control cells at 0h. In MDA-MB-231, there was a 
decrease in migration distance of about 52% upon suppression of DP103, whereas 




Figure 17. Cells migration was reduced when DP103 was down-regulated. siRNA 
against DP103 was transfected in MDA-MB-231 and BT549 cells. They were then 
seeded to confluency. A wound was made and pictures taken at 0h and 48h to depict 
wound healing ability (A). The migration distances of cells were measured at 3 






3.2.3 Knockdown of DP103 on cell migration using non-wound healing assay 
The disadvantage of the wound healing assay is the lack of a defined wound surface 
area, or gap between cells. These wounds can be varying in sizes and widths, which 
inhibit consistent results and create variation from well to well. In addition, 
mechanical wounding induces other processes like anoikis (Grossmann, 2002) when 
some cells are detached from the tissue culture plates. Cells are also damaged 
physically, stimulating repair proceeses or inducing cell death (Miyake and McNeil, 
2003; Woolley and Martin, 2000). All these contribute to experimental noise and 
additional assays should be performed to support findings from the wound healing 
assay. 
 
A two-dimensional non-wound migration assay was done in collaboration with Prof 
Lim Chwee Teck (Division of Bioengineering and Department of Mechanical 
Engineering, NUS) and his team to study the migratory behavior of MDA-MB-231 
with and without DP103 expression as described in materials and methods. Briefly, 
control and transfected cells were allowed to grow to confluency in a cylinder on a 
tissue-culture plate. Fifty cells in each condition were tracked for the distance they 
moved over a period of 24h and the average monolayer edge distance was tabulated 
and plotted on a graph in Figure 18A.  
 
The two-dimensional track plots of the cells were depicted in Figure 18B. The left 
panels, top and bottom, showed cells transfected with control siRNA and the right 
panels, top and bottom showed cells transfected with siRNA against DP103. The top 
panels showed the entire tracks made by the 50 cells while the bottom panels showed 
the ending points of each cell tracks. The starting points of each cell track were 
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moved to the origin of the graph, without changing the directionality of the tracks, 
thus allowing us to observe the effective dispersal of the cells with respect to their 
individual starting points. The centre of mass is defined as the average distance from 
the origin that a single cell would be displaced if it were to represent the 
displacements of all the tracked cells taken together. A circle of this diameter would 
allow an estimate of the number of cells that have actually displaced to larger 
distances than the average displacement for that experiment (as shown in Figure 18B). 
The control condition shows a higher percentage (72%) of cells outside a circle with a 
radius equal to the center of mass compared to 44% when DP103 was suppressed. 
These results further confirm that cell migration and displacement with respect to the 
starting points of the cells were significantly reduced when DP103 was knocked down 
in the MDA-MB-231 cells as compared to the control cells. This higher number of 
cells outside the center of mass showed that they have an increased outward 
dispersion than that in cells with knockdown of DP103. 
 
The data of individual cell tracks from our two-dimensional non-wound migration 
assay was then analyzed for various cell migration parameters in Figure 19. 
Accumulated distance (AD) is an indicator of motility of individual cells whereas 
Euclidean distance (ED) gives an idea about the actual dispersion of the cells with 
respect to their starting positions. On the other hand, confinement ratio is an indicator 
of straightness of the cell paths and reflects the stability of directions of the lamellipod 
polarization over time. Lamellipod polarizations are primarily responsible for laying 
down the foundations for directionality of the cells by affecting focal adhesion 
distribution and hence the contractility of the cells leading to cell motility 
(Dulyaninova et al., 2007; Smith et al., 2007). The control cells (ctsi) showed an 
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increase in the migration distances (AD and ED) of individual cells that significantly 
decreased in the DP103 knock down cells (siDP103) (p=0.05) (Figure 19, top 2 
panels). These results agree with the measurements performed by the wound healing 
and the monolayer edge distances (Figures 17 and 18). Furthermore, there was a 
decrease in the mean cell speed after suppression of DP103 (Figure 19, bottom left 
panel). The confinement ratios however did not show a significant difference 
indicating that knockdown of DP103 decreased the motility of the cells but not their 
directionality (Figure 19, bottom right panel). These observations suggest that 
depletion of DP103 affected the intracellular motility mechanisms in MDA-MB-231 
cells but not the lamellipod polarization.  
 
These results from Figures 17 to 19 indicated that the downregulation of DP103 
expression reduced the overall migration of the cells including the motility of 














Figure 18. Cells after knockdown of DP103 showed decreased cell motility. 
MDA-MB-231 cells were subjected to siRNA knockdown of DP103. Monolayer edge 






Figure 19. Cells after knockdown of DP103 affected the intracellular motility 
mechanisms in MDA-MB-231 but not the directionality. Graphs of different 












3.2.4 Knockdown of DP103 on cell invasion 
Since we had previously shown that DP103 is upregulated in highly invasive breast 
cancer cells, we next explored effects of decreased DP103 expression on tumor cell 
invasion. The matrigel transwell chambers were used, which consist of an 8μm pore 
size PET membrane with a thin layer of matrigel basement membrane matrix. The 
matrigel matrix serves as a reconstituted basement membrane in vitro. The layer 
occludes the pores of the membrane, blocking non-invasive cells from invading 
through the membrane. In contrast, invasive cells are able to detach themselves and 
invade through the matrigel matrix and the membrane pores.  
 
MDA-MB-231 and BT549 cells were seeded into the chamber after siRNA 
transfection had been done the previous day. We removed the matrigel matrix 
membrane from the casing after 24h upon seeding, stained the cells on the underside 
of the membranes and showed that transient knockdown of DP103 resulted in a 
decrease of invading cells through the membrane (Figure 20A), with percentages drop 
in 53.2% and 67.8% in MDA-MB-231 and BT549 respectively (Figure 20B).  
 
In another attempt to reconstitute a micro-environment as closely to in vivo 
conditions, we performed a three-dimensional collagen gel assay in collaboration with 
Prof Lim Chwee Teck and his graduate student, Ms Sun Wei (Division of 
Bioengineering and Department of Mechanical Engineering, NUS). We constructed a 
collagen hydrogel block and seeded MDA-MB-231 cells in the centre of the block. 
Using live microscopy, we tracked each cells over 10h. The tracks taken by the 
control and DP103 knockdown cells were then overlaid and compared. As shown in 
Figure 21A, with the suppression of DP103, there was a slight reduction in the spread 
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of red tracks as compared to that of the control cells, represented by the green tracks. 
Notably, some of the control cells are more dispersed outwards into the collagen gel. 
Cell speed of the cells was also averaged over each track and plotted into a histogram 
(Figure 21B). The medians of cell speed are 14.4μm/h and 10.8μm/h for ctsi and 
siDP103 cells respectively. This meant that the cells treated with siDP103 traveled 
slower than the control cells. Since this was done on a 3D collagen gel, it was an 
indication that with the suppression of DP103 expression, the cells were less invasive, 
further confirming our previous observation using the transwell matrigel chambers. 
 
Pseudopodial protrusion and the dynamic actin cytoskeleton remodeling have long 
been associated with tumor cell migration and invasion (Guirguis et al., 1987; 
Lauffenburger and Horwitz, 1996). MDA-MB-231 cells characteristically show a 
branching morphogenesis. Interestingly, we observed a loss of the pseudopodia 
protrusions in the cell after the suppression of DP103 by siRNA (Figure 22), 
indicating that DP103 indeed has a role in cell metastasis and its depletion halts the 







Figure 20. Cells after knockdown of DP103 showed decreased cell invasion. 2 x 
10
5
 MDA-MB-231 and BT549 cells were seeded into the upper chamber of the 
transwell invasion chamber with serum free media after siDP103 transfection for 48h. 
The membranes of the chambers were stained with crystal violet solution and 
mounted on microscope and pictures taken. Insert shows representative picture in 
higher magnification (A). The number of cells that invaded through the transwell 
invasion chambers were counted in five randomly selected microscope field and 




Figure 21. MDA-MB-231 cells showed less dispersion and reduced cell speed in a 
3D collagen gel upon knockdown of DP103. Cell displacement (μm) tracks over 10 
hours in 3D collagen gel. The tracks of a population of cells (n>50) were adjusted to 
start from the same origin (0,0,0). Control cells are depicted with green tracks while 
siDP103 treated cells are in red (A). The histogram of cells speed averaged over each 
track, track number >50. The height of each column corresponds to the percentage of 





Figure 21. Morphology of MDA-MB-231 cells in the 3D collagen hydrogel after 
knockdown of DP103. Pictures taken from capturing images during live tracking of 



































3.3 Effect of Over-expression of DP103 
To further substantiate our loss-of-function findings above, we then questioned if a 
gain-of-function of DP103 would reverse our previous observations and alter the 
cells’ behavior. 
 
3.3.1 Over-expression of DP103 on cell invasion 
We transfected MDA-MB-231 cells with DP103 plasmid for 24h before seeding some 
of the cells into the matrigel chamber while harvesting the reminding cells for western 
blotting to quantify the amount of overexpression.  
 
Figure 23A showed successful overexpression of DP103 protein in MDA-MB-231 
cells, indicating that the cells in the invasion assay were also overexpressed with 
DP103. This forced expression of DP103 significantly promoted invasion by about 
1.5 folds as observed in the transwell invasion assay (Figure 23B and C).  
 
Importantly, when we repeated the same setup using MCF10A, a normal human 
breast epithelial cell line, with low invasive potential and a low level of DP103 
expression (as seen previously in Figure 9), it also showed increased invasion by at 
least 4 folds upon forced expression of DP103 (Figure 24). These strongly suggest 
that increasing levels of DP103 alone would result in transforming cells transforming 
into an invasive phenotype. Henceforth, again, for the first time, we demonstrate the 






Figure 23. Over-expression of DP103 in MDA-MB-231 increased cell invasion. 
MDA-MB-231 cells were transfected with pcDNA3 and pcDNA3-FLAG-DP103 (F-
DP103). Cells were harvested and lysed, and cell extracts were immunoblotted with 
anti-DP103 antibodies. The densitometry values (indicated below the blot) were 
normalized with respect to the β-actin control (A). MDA-MB-231 cells were prepared 
for invasion assay (B). MDA-MB-231 cells that invaded through the chambers were 




Figure 24. Over-expression of DP103 in MCF10A increased cell invasion. 
MCF10A cells were transfected with pcDNA3 and pcDNA3-FLAG-DP103 (F-
DP103). Cells were harvested and lysed, and cell extracts were immunoblotted with 
anti-DP103 antibodies. The densitometry values (indicated below the blot) were 
normalized with respect to the β-actin control (A). MCF10A cells were prepared for 
invasion assay (B). MCF10A cells that invaded through the chambers were counted in 







3.3.2 Over-expression of DP103 in a metastasis qPCR array 
Cell invasion requires the complex coregulation of cytoskeletal reorganization and 
cell motility as well as proteolyis and interaction with the extracellular matrix. Since 
DP103 is a metastasis-associated gene and over-expression of DP103 increases 
metastasis, we seek to identify the metastatic genes modulated by it. 
 
We established a 'metastatic qPCR array' in which 13 genes known to be involved in 
metastasis were selected to be used for the array (Table 4). β-actin, HPRT and 
GAPDH were used as 'housekeeping' genes. Using BT549 cells with or without 
DP103 overexpression by lentivirus infection, we measured the mRNA levels of these 
13 genes.  
 
The over-expression of DP103 did not alter the mRNA expression of genes like 
NME1, PLAU, SERPINB5 or MTA1, but several other genes like MMP1, TIMP1 
and TIMP3 were upregulated slightly. Significantly, MMP9 or matrix 
metalloproteinase 9 was increased by 2.66 folds, indicating that MMP9 might be a 











Gene Gene Name References 
MTA2 Metastasis associated gene 2 (Fu et al., 2011; Li et al., 2010) 
NME1 Nucleoside diphosphate kinase A 





(Yoshizawa et al., 2011) 




(Huang et al., 2011; Margheri et 
al., 2005) 
MMP1 Matrix Metalloproteinase 1 
(Egeblad and Werb, 2002; 
Milde-Langosch et al., 2004) 
SERPINB5 
Serpin peptidase inhibitor, clade B 
member 5 
(Findeisen et al., 2008) 
MMP2 Matrix Metalloproteinase 2 
(Bourboulia and Stetler-
Stevenson, 2010; Li et al., 2004) 
SERPINE1 
Serpin peptidase inhibitor, clade E 
member 1 
(Nagahara et al., 2010) 
MMP9 Matrix Metalloproteinase 9 
(Adamson et al., 2000; Liu et al., 
2010; Wu et al., 2008) 
TIMP1 Metallopeptidase inhibitor 1 
(Baramova et al., 1994; Jinga et 
al., 2006) 
MTA1 Metastasis associated gene 1 
(Mahoney et al., 2002; Marzook 
et al., 2011) 
TIMP3 Metallopeptidase inhibitor 3 (Bourboulia and Stetler-
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Stevenson, 2010; Brew and 
Nagase, 2010) 
 
Table 4. List of metastatic related genes and references that are used in the 












































Gene Gene Name Fold Change (±SD) P-value 
MTA2 Metastasis associated gene 2 1.173883 (±0.023156) 0.1418 




1.089051 (±0.231132) 0.2914 




1.154275 (±0.026637) 0.0499 
MMP1 Matrix Metalloproteinase 1 1.88218 (±0.165944) 0.0445 
SERPINB
5 
Serpin peptidase inhibitor, clade B 
member 5 
1.040501 (±0.335911) 0.5561 
MMP2 Matrix Metalloproteinase 2 0.80275 (±0.110911) 0.6882 
SERPINE
1 
Serpin peptidase inhibitor, clade E 
member 1 
0.845209 (±0.218096) 0.5754 
MMP9 Matrix Metalloproteinase 9 2.668643 (±0.000182) 0.0026 
TIMP1 Metallopeptidase inhibitor 1 1.535293 (±0.062558) 0.0043 
MTA1 Metastasis associated gene 1 1.225943 (±0.067582) 0.0387 
TIMP3 Metallopeptidase inhibitor 3 1.659162 (±0.224292) 0.0372 
 
Table 5. Effects of forced expression of DP103 in BT549 cells on expression of 
genes functionally involved in metastatic progression. Results are represented as 
fold change in mRNA levels in BT549-DP103 cells relative to the control cells. Fold 
change values are representative of three independent mRNA replicates. Values less 
than 1 indicate decreased expression and more than 1 indicates increased expression 






3.4 Is MMP9 expression and activity modulated by DP103? 
MMP9 belongs to the family of zinc-dependent endopeptidases capable of degrading 
all kinds of extracellular matrix in normal physiological processes, such as embryonic 
development, reproduction and tissue remodeling, as well as in disease processes like 
arthritis and metastasis. MMP9, in particular, is capable of degrading type IV collagen 
found richly in basement membrane and had been observed to be strongly correlated 
in malignant breast tumors (Hanemaaijer et al., 2000). 
 
Till this point, we showed MMP9 to be significantly upregulated when DP103 was 
overexpressed in BT549 invasive breast cancer cells. In order to validate this 
observation, as well as to confirm if MMP9 is functionally active in increasing 
invasion as observed previously, we returned to our previous human patients and cell 
lines models and sought to elucidate a possible relationship between MMP9 and 
DP103. 
 
3.4.1 Expression of MMP9 in breast cell lines and tissues  
Using the same panel of breast cell lines from Figure 9 to maintain consistency in our 
results, we screened for MMP9 mRNA and protein expression levels.  
 
In concordant to expression levels of DP103, we showed that the highly invasive cell 
lines, MDA-MB-231 and BT549 display the highest levels of basal MMP9 gene 
expressions while the low metastatic and normal breast cell lines, BT474, MCF10A 
and 184A1 display the lowest levels of MMP9 (Figure 25A). Not surprisingly, we saw 
the same trend in their protein expressions (Figure 25B).  
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We then used the same cohort of human patient breast tissues from Figure 12 and 
performed real-time PCR to analyze MMP9 mRNA expression. Similarly, the highest 
expression of MMP9 was seen in the primary breast tumor tissues that metastasized 
compared to the primary breast tumor tissues that did not. The breast benign tissues 
which served as a control displayed the lowest mRNA levels of MMP9 (Figure 26).  
 
Collectively, we demonstrated similar findings as shown in known literatures that 
high MMP9 expression is associated with invasiveness in cancer cells (Gong et al., 








Figure 25. MMP9 expression in a panel of breast cell lines. RNA of different 
breast cell lines were extracted and qPCR were performed with MMP9 primer, 
normalized with 18S and represented as fold difference (A). Cells of different breast 
cell lines were harvested, lysed for protein and western blotting was performed using 





Figure 26. MMP9 expression in human breast benign, non-metastatic (Non-Met) 
and metastatic (Met) tissues. Samples were collected and tested for MMP9 mRNA 


















3.4.2 Correlation of MMP9 with DP103 expression  
We have shown that both DP103 and MMP9 levels are high in aggressively invasive 
cells lines and tissues. Hence, a Pearson correlation coefficient analysis was done to 
measure the association between these two genes. 
 
The Pearson correlation coefficient or Pearson product-moment correlation coefficient 
is widely used as a measure of the strength of linear dependence between two 
variables. The correlation coefficient ranges from -1 to 1. A value of 0 indicates that 
there is no association between the two variables. A value greater than 0 indicates a 
positive association and a value less than 0 indicates a negative association. 
Generally, a value ranging from ±0.1 to ±0.3 has a small strength of association. A 
value ranging from ±0.3 to ±0.5 has a medium strength of association and value 
ranging from ±0.5 to ±1.0 has a strong strength of association. 
 
From the panel of breast cell lines, the Pearson correlation coefficient was calculated 
to be r = 0.913, suggesting a strong correlation of DP103 to MMP9 expressions 
(Figure 27A). Furthermore, from the cohort of 63 human breast tissues, the Pearson 
correlation coefficient was r = 0.513, indicating that there is indeed a positive 







Figure 27. DP103 and MMP9 levels are correlated. Pearson’s Correlation 
Coefficient was determined between the mRNA expression of DP103 and MMP9 in 
various breast cell lines. DP103 expression was positively correlated with MMP9 
expression (A). DP103 and MMP9 expression levels in 63 human breast patients were 










3.4.3 High expressions of DP103 and MMP9 lead to poor prognosis 
Since high MMP9 expression is closely associated with poor prognosis in other 
cancer types like nasopharyngeal, squamous cell carcinoma and lymphoma (Liu et al., 
2010; Mitra et al., 2008; Sakata et al., 2004), we performed immunohistochemical 
(IHC) staining of tissues from the same patients cohort used in Figures 7 and 8 for 
MMP9 expression.  
 
For comparison of survival outcomes in relation to DP103 and MMP9 expressions, 
the group with intermediate (2+) and high (3+) pathological scoring was classified as 
“high” while those with low (1+) or undetectable (0) were classified as “low”. Using 
this grouping, a Kaplan-Meier analysis was performed to investigate the association 
of MMP9 and DP103 expressions with survival in AJCC (American Joint Committee 
on Cancer) stages 3 and 4 breast cancer patients with the differences assessed by log-
rank.  
 
The Kaplan-Meier analysis is an estimator for estimating the survival function from 
life-time data. It is often used to measure the fraction of patients living for a certain 
amount of time after treatment. From the cohort of breast cancer patients, we screened 
for their DP103 levels and selected those showing elevated levels of DP103. In this 
subcohort, we measured their MMP9 levels. The survival curves in Figure 28A show 
that in these patients with abundant DP103 expression, they had poor overall survival 
when their MMP9 expression was also high (n=55, p=0.029). Figure 28B showed 





Figure 28. Patients with high DP103 and MMP9 expressions had lower survival 
rates. Kaplan-Meier curves showing differences of MMP9 expression in relation to 
surviving duration in high DP103 expressing cases (n=55). Cases with high MMP9 
and high DP103 expression (mean, 69; months, n=21) have significantly shorter 
survival duration (p=0.029) compared to those with low MMP9 and high DP103 
expression (mean, 86 months; n=34). Cases that are still surviving are censored at the 
date of last follow-up (denotes by squares and circles on the line plots) (A). 
Representative pictures of immunohistochemical staining of breast cancer biopsies 










3.4.4 Suppression of DP103 reduced MMP9 transcript and protein levels 
In an attempt to establish a direct link between DP103 and MMP9, DP103 was 
suppressed via siRNA technology. This resulted in a significant decrease in MMP9 
mRNA levels at both 24h and 48h compared to the control cells in all the three 
invasive breast cancer cell lines, MDA-MB-231, BT549 and HS578t (Figure 29A). 
Additionally, the decrease in MMP9 mRNA transcripts related well with a drop in its 
protein levels too (Figure 29B), an indication that DP103 might be regulating the 
transcription activity of MMP9. 
 
MMPs are known to be pro-enzyme and a cleavage of the pro-domain is necessary for 
the activation of this enzyme to perform its activity. Henceforth, to confirm the 
decrease in MMP9 protein levels corroborated with the decreased activity of the 
enzyme, we performed a gelatin gel zymography in MDA-MB-231.  
 
MMP9 enzyme is capable of degrading gelatin. Since active MMP9 is a secreted 
enzyme, we collected the supernatant after transfection and ran an electrophoresis gel 
that was mixed with gelatin. If the enzyme is active, gelatin will be degraded in the 
gel and a clear band will be seen after staining the gel with Coomassie Blue. The 
gelatin gel zymography can also detect the activity of MMP2, which belongs to the 
same subfamily as MMP9. 
 
As a positive control, we treated MCF10A cells with increasing concentrations of 
Tumor Necrosis Factor α (TNFα) and collected the cells for gelatin gel zymography. 
Upon such stimulation, MMP9 activity increases (Stuelten et al., 2005) and this is 
shown in Figure 30 with increasing clearing of the bands (Lanes 1-4). When DP103 
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was depleted in MDA-MB-231 cells, the clear band disappeared, indicating a loss of 
MMP9 activity (Figure 30, lanes 5-6). MMP2 activity, on the other hand, showed no 
effect to depletion of DP103 (Figure 30, bottom bands). 
 
Thus, we can conclude that DP103 protein is modulating the transcriptional 











Figure 29. Knockdown of DP103 reduced MMP9 levels. MDA-MB-231, BT549 
and HS578t cells were transfected with control siRNA (ctsi) and siRNA against 
DP103 (siDP103). Cells were harvested and lysed for RNA and protein. qPCR and 
western blotting were performed with DP103 and MMP9 primers and antibodies, 
showing that MMP9 mRNA (A) and protein levels (B) decreased after DP103 











Figure 30. MMP9 activity was decreased with suppression of DP103. MDA-MB-
231 cells were transfected with control or siRNA against DP103. For a MMP9 
control, MCF-10A cells were treated with 1, 5, 10 or 30ng/ml for 24 h. Growth media 
were collected and MMP9 activity was measured in gelatin zymography gel. L 


















3.4.5 Invasion was inhibited with use of specific MMP9 inhibitor 
We had shown that MMP9 activity was decreased by downregulating DP103 and the 
latter brought about the inhibition of metastasis in invasive breast cancer cell lines. 
However, in our 'metastatic qPCR array', we saw several other MMPs also 
upregulated in the process even though the fold changes are not as elevated as MMP9. 
In order to confirm that MMP9 is the main molecular effector of this observation, we 
performed matrigel transwell assay with or without several MMPs inhibitors. 
 
We used a specific MMP2/9 inhibitor (SB-3CT) and a broad spectrum MMPs 
inhibitor (GM6001) and showed that invasion of MDA-MB-231 cells through the 
matrigel matrix was inhibited by about 38% by both inhibitors (Figure 31). We then 
treated the cells with specific MMP9 inhibitor and observed that it prevented the cells 
from migrating through the matrix by about 50%. Importantly, forced overexpression 
of DP103 alone increased the invasion of MDA-MB-231. However, in the presence of 
the specific MMP9 inhibitor, this effect was abrogated when DP103 was forced 
overexpressed (Figure 32). These suggest that MMP9 is the major endopeptidase 









Figure 31. Cell invasion is also inhibited by pan-MMPs and specific MMP2/9 
inhibitors. 2 x 10
5
 MDA-MB-231 cells were seeded into the upper chamber of the 
tranwell invasion chamber with serum free media with either MMP2/9 inhibitor (SB-
3CT, 10μM) or pan-MMPs inhibitor (GM6001, 50μM). After 24h, the membranes of 
the chambers were stained with crystal violet solution and mounted on microscope 
slides and pictures taken. Insert shows representative picture in higher magnification 
(A). The number of cells that invaded through the transwell invasion chambers were 
counted in five randomly selected microscope fields and plotted on a graph (B). 









Figure 32. Invasion was reduced with specific MMP9 inhibitor. 2 x 10
5
 MDA-
MB-231 cells transfected with either empty vector (EV) or over-expressed with F-
DP103 were seeded into the upper chamber of the tranwell invasion chamber with 
serum free media with or without MMP9 Inhibitor I (1μM). After 24h, the membranes 
of the chambers were stained with crystal violet solution and mounted on microscope 
slides and pictures taken. Insert shows representative picture in higher magnification 
(A). The number of cells that invaded through the transwell invasion chambers were 
counted in five randomly selected microscope fields and plotted on a graph (B). 
MMP9 specific inhibitor did not show any cytotoxicity from crystal violet assay (C).  







3.5 How does DP103 regulate MMP9 expression? 
Transcriptional regulation of MMP9 involves a relatively large repertoire of 
transcriptional factors that includes AP-1, AP-2, Ets, NF-κB, and SP-1 out of which 
AP-1 (Adamson et al., 2000; Milde-Langosch et al., 2004; Nair et al., 2008), and NF-
κB (Chou et al., 2010; Ricca et al., 2000) are postulated to be the major regulators in 
cancers. Given that depletion of DP103 expression in three invasive cell lines 
decreased MMP9 mRNA, we sought to elucidate the transcription factor DP103 is 
acting on.  
 
3.5.1 Suppression of DP103 inhibits NF-B activity 
The dual-luciferase reporter assay serves to measure the activity of the reporter gene 
in question. The firefly luciferase reporter is measured first with the first 'glow-type' 
luminescent signal. After quantifying this, the reaction is quenched and the Renilla 
luciferase reaction is initiated. The first reading was then normalised with Renilla 
reading and the total protein concentration. 
 
To determine whether NF-κB or AP-1 activity is affected when subjected to the 
downregulation of DP103, MDA-MB-231 cells were first transfected with siDP103 
for 24h. They were then transiently transfected with either a NF-κB responsive firefly 
luciferase reporter or an AP-1 responsive firefly luciferase reporter. As a control for 
cell numbers and transfection efficiency, cells were also co-transfected with Renilla 
vector. 24h later, measurements of the respective reporter activity were made. From 
Figure 33, we observed that the activity of NF-κB was reduced with suppression of 




In order to confirm our luciferase assay results, we did an electrophoretic mobility 
shift assay or EMSA. EMSA is an affinity electrophoresis technique used to study 
protein-DNA interactions and it can determine if a protein is capable of binding to a 
given DNA sequence. We incubated the nuclear extracts with a radioactive labeled 
oligonucleotide probe which contains the specific recognition sequence for NF-κB. If 
NF-κB subunit are present in the nuclear extracts, their interaction with the probe 
shifts the band of the labeled probe up since the complex of probe and NF-κB subunit 
has a lower electrophoretic mobility than the probe alone. The intensity of the shifted 
band is a measure for the amount of NF-κB in the nuclear fraction.  
 
In the first 2 lanes of Figure 34A (left), we showed that while the basal NF-κB 
activity is high in untransfected cells, it decreased drastically upon suppression of 
DP103. Oct-1 probe served as a control for even loading across samples (Figure 34A, 
right). 
 
The microenvironment of cancers are known to be under constant pressures, for 
example hypoxia or genotoxic stress. This, in turn, causes the activation of signal 
transduction pathways to deal with such stress. The NF-κB pathway is one of the 
main pathway to transcribe to overcome such ordeal (Lisanti et al., 2010). As such, 
we wanted to mimic the physiological conditions of the tumor to be under genotoxic 
stress. Given that NF-B transcriptional activity is also known to be affected by 
genotoxic stress inducers like doxorubicin, etoposide (VP16) and camptothecin 
(Huang et al., 2003; Lee et al., 2011; Mabb et al., 2006), we sought to investigate if 
depletion of DP103 would have any effects in the presence of such inducers. The NF-
κB binding ability increased under the treatment of doxorubicin, etoposide or 
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camptothecin on MDA-MB-231 as compared to the untreated cells. However, after 
downregulation of DP103, the binding ability of NF-κB decreased in all three drug 
treatments (Figure 34A, left). Figure 34B showed successful knockdown of DP103 
protein by siRNA in the EMSA setup.  
 
Additionally, it is of interest to note that there is a concomitant increase of DP103 
upon stimulation by NF-κB genotoxic stress inducers (Figure 34B), leading to a 
possibility that DP103 protein expression may be induced by activation of NF-κB 
itself. This warrants a need for further in-depth analysis.  
 
Following this observation, we further validated the EMSA results by returning to 
perform luciferase assay again, but with the addition of NF-κB genotoxic stress 
inducers. Figure 35 showed that while the basal NF-B activity increased with the 
respective genotoxic drugs, when depleted of DP103, the increment in NF-B activity 
was less prominent. On the other hand, the AP-1 activity was not altered regardless of 
genotoxic stimuli or suppression of DP103 (Figure 36), paralleling the findings from 








Figure 33. Downregulation of DP103 caused a decrease in NF-κB luciferase 
activity but not AP-1. Control siRNA and siDP103 treated MDA-MB-231 cells were 
transfected with Renilla and luciferase reporter plasmid containing NF-κB or AP-1. 
The cells were then harvested with passive lysis buffer to carry out luciferase assay. 
Results are expressed in fold difference, and are the average of 3 separate 








Figure 34. Downregulation of DP103 decreases NF-κB DNA binding ability in 
EMSA. MDA-MB-231 cells were transfected with control or siRNA against DP103. 
Cells were treated with 25μM doxorubicin (DOX) for 60 min, 10μM VP16 for 90 min 
and 10μM CPT for 120 min. Total cell extracts were prepared, NF-κB activities were 
measured by EMSA. An Oct-1 probe was served as an EMSA control (A). Western 






Figure 35. Downregulation of DP103 decreases NF-κB luciferase activity under 
genotoxic stimuli. Control siRNA and siDP103 treated MDA-MB-231 cells were 
transfected with Renilla and luciferase reporter plasmid containing NF-κB. The cells 
were subsequently stimulated with 10μM CPT (A) or DOX (B) for 18h and 24h and 
then harvested with passive lysis buffer to carry out luciferase assay. Results are 







Figure 36. Downregulation of DP103 does not decrease AP-1 luciferase activity 
under genotoxic stimuli. Control siRNA and siDP103 treated MDA-MB-231 cells 
were transfected with Renilla and luciferase reporter plasmid containing AP-1. The 
cells were subsequently stimulated with 10μM CPT (A) or DOX (B) for 18h and 24h 
and then harvested with passive lysis buffer to carry out luciferase assay. Results are 








3.5.2 Suppression of DP103 increased cells' sensitivity to genotoxic drugs 
Since NF-κB but not AP-1 transcriptional activity was affected by DP103, we 
postulated that the downstream targets of NF-κB would also be downregulated if the 
activity decreased, but not so in AP-1. Hence, we checked some of NF-κB and AP-1 
regulated genes. 
 
In addition to MMP9, ICAM-1 and CXCR4 are also regulated by NF-κB (Helbig et 
al., 2003; Xue et al., 2009). While the levels of these proteins decreased upon 
downregulation of DP103, the protein level of c-Jun, regulated by AP-1 (Kaminska et 
al., 2000) remained unchanged (Figure 37). 
 
Since NF-B activation by genotoxic stimuli is linked to cell viability and apoptosis 
(Karin, 2006), we determined the viability of MDA-MB-231 cells under genotoxic 
stress when they are depleted of DP103 in another attempt to confirm the link 
between DP103 to NF-κB. Using camptothecin and doxorubicin, both displayed cell 
death of about 20 to 30% in untransfected cells. However, when DP103 levels were 
suppressed, the viability of the cells were compromised to 50.32% and 53.44% in the 
presence of camptothecin or doxorubicin respectively (Figure 38). Representative 
pictures of the staining of the cells were shown at the bottom of the graphs in Figure 
38. 
 
Collectively, we had confirmed that DP103 interferes with the transcriptional activity 





Figure 37. Downregulation of DP103 reduces NF-κB targeted proteins, but not 
that of AP-1. MDA-MB-231 cells were transfected with siDP103 for 48h and 
subjected to CPT (10μM) stimulation at the indicated time. Cells were harvested and 









Figure 38. Downregulation of DP103 caused cells to be more sensitive to 
genotoxic drugs. MDA-MB-231 cells were transfected with ctsi or siDP103 and 
treated with or without 25μM CPT (A) or 10 μM Dox (B) for 48h, before staining by 
crystal violet solution to determine cell viability. Scanned pictorial representation of 
the treatment (bottom) before dissolving the crystals and graphs showing percentage 

















3.6 How does DP103 fit into the NF-B pathway? 
The NF-B family consists of several important proteins and under different stimuli, 
they act under different pathways to elicit different cellular responses. We had 
established an association between DP103 and the NF-B pathway. There are 
numerous possibilities as to which DP103 may interfere with the transcriptional 
activity of NF-B. DP103 may act to regulate the levels of important NF-B proteins 
like p65, NEMO or IKK2. On the other hand, it might be possible that DP103 is 
involved in some post-translational modifications like phosphorylation or 
SUMOylation of NF-B members. Our group previously showed DP103 to be 
modulating SF-1 via SUMO modifications (Lee et al., 2005b), thereby causing its 
repression. Henceforth, we speculated a possible role of DP103 in SUMOylation in 
the NF-κB pathway. 
 
3.6.1 DP103 does not change endogenous levels of NF-B related proteins 
We first tested the levels of some of the NF-κB members after downregulation of 
DP103 and showed that there was no effect in the protein levels of p65, NEMO and 
IKK2 (Figure 39). Hence, we ruled out the possibility that DP103 is directly 










Figure 39. DP103 does not regulate NF-κB members. MDA-MB-231 cells were 
transfected with control siRNA (ctsi) and siRNA against DP103 (siDP103). Cells 


















3.6.2 DP103 interacts with NEMO and mediates its SUMOylation under 
genotoxic stress 
Since we have previously showed that the DP103 is required for activation of NF-B 
activity under genotoxic stress, we turned our focus to post-translational modification 
that occurred under genotoxic stimuli.  
 
Huang et al., 2003 first published that IB kinase gamma (IKKγ) regulatory subunit 
NEMO (NF-B essential modulator) undergoes SUMOylation by SUMO-1 under 
genotoxic stress inducers like camptothecin and doxorubicin. Hence, we explored a 
possible physical interaction between DP103 and NEMO. Genotoxic agents were 
used in our setup to enhance the SUMOylation effects on NEMO. 
 
We treated MDA-MB-231 cells with camptothecin and collected the lysates for 
immunoprecipitation assays. We show for the first time that DP103 interacts with 
NEMO in unstimulated conditions as well as with camptothecin (Figure 40, lanes 1-
3). We went on to test if SUMOylation of NEMO is affected and observed a time 
dependent increase in SUMOylation upon camptothecin treatment (Figure 40, lanes 1-
3). Furthermore, this SUMOylation is diminished with knockdown of DP103 (Figure 
40, lanes 4-6).  
 
Taken together, we concluded that DP103 is necessary for the SUMOylation of 






Figure 40. DP103 is required for the SUMOylation of NEMO. Control and siRNA 
against DP103 treated MDA-MB-231 cells were stimulated with 10μM CPT for 1h or 
2h and then harvested and lysed. The cell lysates were immunoprecipitated with 
NEMO antibody and then evaluated by Western blotting with indicated antibodies. 





























3.6.3 RNA helicase activity of DP103 is not required for SUMOylation of NEMO 
and increased metastasis 
DP103 belongs to the DEAD box family of helicases, which shares several conserved 
and unique motifs, including the Walker A and B motifs. These motifs are involved in 
the binding of nucleoside triphosphates required for its helicase activity (Linder, 
2006). Some members in this family like DDX3 and DDX1 have been found to 
require its ATP-dependent helicase for their functions (Garbelli et al., 2011; Ishaq et 
al., 2009), while several others like p68 do not (Clark et al., 2008; Zhao and Jain, 
2011). 
 
To investigate if the helicase activity of DP103 is required for SUMOylation of 
NEMO, we generated a full length DP103 GNT mutant where the critical lysine 
residue (GKT) that is needed to bind ATP was mutated to an asparagine residue, GNT 
(Caruthers and McKay, 2002; Fry et al., 1986; Kim et al., 1998) (Figure 41A). 
Changing the conserved GKT to GNT has been shown to reduce ATP binding in 
RNA helicases by 98% (Richter et al., 1996). 
 
We subsequently show forced overexpression of the helicase-dead mutant (GNT) 
retained its ability to SUMOylate NEMO just as efficient as forced overexpression of 
the wild type DP103 (WT) (Figure 41B). Additionally, the helicase-dead mutant 
(GNT) also retained its ability to induce invasion in MDA-MB-231 cells (Figure 42), 








Figure 41. Helicase activity of DP103 is not required for SUMOylation of 
NEMO. Pictorial map showing the FLAG-tagged wild-type (WT) and single amino 
acid mutated at helicase domain (GNT) of DP103 (A). MDA-MB-231 cells were 
stimulated with 10μM CPT for 2h and then harvested and lysed. The cell lysates were 
immunoprecipitated with NEMO antibody and then evaluated by Western blotting 







Figure 42. Helicase activity of DP103 is not required for increased invasion of 
MDA-MB-231 cells. 2 x 10
5
 MDA-MB-231 cells transfected with either empty 
vector (EV), wild-type DP103 (WT) or GNT mutant (GNT) were seeded into the 
upper chamber of the tranwell invasion chamber with serum free media after siRNA 
transfection for 48h. The membranes of the chambers were then stained with crystal 
violet solution and mounted on microscope slides and picture taken. Insert shows 
representative picture in higher magnification (A). The number of cells that invaded 
through the transwell invasion chambers were counted in five randomly selected 







3.6.4 Genotoxic agent increases interaction of DP103 with PIASy and SENP2 
Mabb et al., 2006 showed that PIASy (protein inhibitor of activated STATy) interacts 
with NEMO, enhances NEMO SUMOylation and activates NF-κB in response to 
genotoxic agents. Furthermore, PIASy preferentially stimulates SUMO modification 
of NEMO by SUMO-1, but not SUMO-2 and SUMO-3. SENP1, one of the six 
Sentrin/SUMO-specific proteases, had also been shown to be able to deSUMOylate 
NEMO in vitro. 
 
In another paper, Lee et al., 2011 observed that SENP2, a Sentrin/SUMO-specific 
protease, is the major SUMO protease that interacts most efficiently with NEMO 
(instead of SENP1) and inhibits NF-κB activation induced by genotoxic agents. 
SENP2 was also found to be more proficient than SENP1 in deSUMOylating NEMO. 
 
We thus seek to test in our system if DP103 associates with PIASy, SENP1 and/or 
SENP2. We first attempted to establish PIASy-mediated SUMOylation of NEMO 
under camptothecin treatment in our system using MDA-MB-231 cells. We showed 
that PIASy indeed enhances the SUMOylation of NEMO (Figure 43A). Subsequently, 
we explored the possibilities of their associations by performing a co-IP assay. 
Without VP16 treatment, there was no interaction between DP103 and PIASy, SENP1 
or SENP2 (Figure 43B, Lanes 1-6). Upon VP16 treatment, DP103 interacted with 
PIASy and SENP2. SENP1 interaction is, however, not inducible (Figure 43B, Lanes 





Figure 43. Genotoxic agent increased interaction of DP103 with PIASy and 
SENP2. MDA-MB-231 cells were transfected with Flag-DP103 or HA-PIASy. Cells 
were treated with CPT (10μM) for 1h before harvested, lysed and performed IP with 
anti-NEMO antibody. They were analysed by immunoblotting using anti-SUMO1 
antibody (A). HEK293 cells were transfected with Flag-DP103 along with the 
indicated constructs tagged with HA. Cells were either left untreated or treated with 
VP16 (10μM) for 1h and processed for co-IP analysis. Δ: NEMO band, †: PIAS band, 




3.6.5 DP103 enhances NEMO-PIASy interaction while decreasing NEMO-
SENP2 interaction 
We have previously showed that increased DP103 enhances SUMOylation of NEMO 
(Figure 40). It is however unclear if DP103 helps in enhancing SUMOylation directly 
or inhibits the deSUMOylation machinery. 
 
Since PIASy is the E3 ligase for SUMOylation of NEMO, we seek to determine if the 
addition of both DP103 and PIASy could cause any alterations to this effect. At the 
same time, we would like to determine if DP103 serves to inhibit deSUMOylation of 
NEMO with SENP2. 
 
We performed an in vitro SUMOylation assay with recombinant SUMO-1, SUMO E1 
and Ubc9 (SUMO E2) protein, together with PIASy, DP103 and/or SENP2. The in 
vitro SUMOylation assay helps to confirm if a particular protein is involved in the 
SUMOylation process. From Figure 44A, we observed that while PIASy alone is able 
to SUMOylate NEMO, the addition of DP103 enhanced in vitro SUMOylation of 
NEMO mediated by PIASy (Lanes 3 and 4). It is however, not clear whether DP103 
prevented deSUMOylation by SENP2 in vitro (Lane 5) and further analysis need to be 
carried out to confirm this. It is necessary to note that these samples were ran on a 8% 
acrylamide gel for a prolonged period of time (2h at 130V) in an attempt to separate 
the PIASy and SENP2 bands, as seen in Figure 44A, right. Samples from Figure 43B 
were ran on a 4-12% gradient acrylamide gel at 130V for 1h, thus the appearances of 




When different amounts of DP103 were analysed in their abilities to interact with 
NEMO, SENP2 and PIASy, we observed that increasing DP103 increases NEMO-
DP103 interaction while at the same time increases NEMO-PIASy interaction. We 





















Figure 44. DP103 enhanced NEMO-PIASy interaction while decreased NEMO-
SENP2 interaction. In vitro SUMOylation was performed with recombinant SUMO-
1, SUMO E1 and Ubc9 proteins. The samples were then subjected to SDS-PAGE and 
immunoblotted with indicated antibodies (A). HEK293 cells were transfected with 
Myc-NEMO, Flag-SENP2, HA-PIASy and/or increasing dose of Flag-DP103. After 
24h, cells were incubated with CPT (10μM) for 1h, performed IP using anti-Myc 







3.6.6 DP103 expression in the nucleus is increased in high grade tumors 
Given that SUMOylation of NEMO is a nuclear event such that free NEMO need to 
be translocated into the nucleus before the series of post-translational modifications 
can occur (Huang et al., 2003), the subcellular localization of DP103 expression will 
be of immersed interest should the interaction between DP103 and NEMO we 
elucidated proved to be true. 
 
We took several breast patient tissues from normal breast epithelium to differential 
grades of infiltrating ductal carcinomas and stained for DP103 protein. Indeed, 
increased expression of DP103 in the nucleus could be observed in high grade tumors 
during breast cancer progression. The normal breast epithelial cells showed mild to 
moderate cytosolic expression, further signifying its very low constitutive levels in 
normal breast cells also confirmed earlier in Chapter 3.1 (Figure 45).  
 
Clearly, DP103 has once again showed its increase of expression in breast 
tumorigenesis and its augmentation into a nuclear expression in the Grade 3 tumors 
may be an indication of increased interaction with NEMO and thereby lead to 
invasion and metastasis. 
 
Figure 45. Increased DP103 expression in nucleus of high grade tumors. DP103 





3.7 Targeting DP103 clinically 
We have shown DP103 to be a prognostic marker for metastatic breast cancer, and it 
is essential for SUMOylation of NEMO, thereby activating of NF-κB. An efficient 
method of targeting DP103 specifically will therefore be a good therapeutic option for 
the treatment of metastatic breast cancers in human. 
 
Therapeutic use of siRNA over the years has been plagued with several limitatations, 
such as low enzymatic tolerability, poor cellular uptake, cellular internalization as 
well as non-specific targeting of tissues (Guo et al., 2010; Pirollo and Chang, 2008; 
Tamura and Nagasaki, 2010). As such, many groups have tried to design 
nanoparticles (Hasan et al., 2011), cation polymer (Nimesh et al., 2011) or liposomes 
(Kundu et al., 2011) to encapsulate the siRNA before delivering them in vivo. Despite 
that, the efficacy and safety issues of each method need to be intensively addressed 
before bringing them into clinical applications (Shim and Kwon, 2010). Hence, we 
decided to adopt the use of a clinically available drug, belonging to the family of 
statins in bid to inhibit DP103 (See Introduction, Chapter 1.6.3). Given the known 
link of statins to NK-κB as well as to cancer metastasis, and the elucidation of DP103 
to have a pivotal role in the progression of metastasis, we speculate that actions of 









3.7.1 Statins downregulate DP103 expression 
We selected two statins, Simvastatin (Trade name: Zocor) and Lovastatin (Trade 
name: Mevacor) for use in this project. Simvastatin is a synthetic derivate from a 
fermentatio product of Aspergillus terreus, while Lovastatin is derived from 
fermentation of oyster mushrooms and red yeast rice (Kang et al., 2009; Sassano and 
Platanias, 2008). 
 
Following Simvastatin and Lovastatin treatments in MDA-MB-231 cells, we observed 
a dose-dependent decrease in the levels of CXCR4 and MMP9 which are downstream 
targets of NF-κB as reported by others (Biswas et al., 2001; Helbig et al., 2003; 
Rehman and Wang, 2008). More importantly, we also noticed similar trend of 














Figure 46. Statins are able to downregulate DP103 expressions. MDA-MB-231 
cells were subjected to Simvastatin and Lovastatin treatments. RNA and protein were 






3.7.2 Overexpression of DP103 rescues the inhibitory effect of simvastatin on 
invasion 
Since Simvastatin is able to downregulate DP103 and MMP9, and that we have 
previously shown that DP103 controls the expressions of NF-κB related protein via 
positive modulation of its activity, it is hypothesized that the drug brings down the 
expression of DP103, which inhibits NF-κB activity, thereby causing a decrease in 
MMP9 levels and reduced invasion. 
 
To test this hypothesis, we designed a rescue experiment where we treated MDA-MB-
231 cells transfected with either empty vector or Flag-DP103 with Simvastatin. From 
Figure 47C, we showed the effective overexpression of DP103, and that this 
upregulation alone is able to increase invasion by two folds from the transwell 
invasion assay (Figure 47A top panel). Additionally, as with reported observations 
(Kang et al., 2009), Simvastatin alone is able to inhibit invasion by about 50% (Figure 
47A left panels and Figure 47B). However, when the overexpressed cells were treated 
with Simvastatin, the anti-invasive effect of the drug is rescued with the percentage of 
invaded cells reduced by almost 100% (Figure 47). 
 
Collectively, we show the effective use of statins to downregulate DP103 expression 
in cancer cells. This suppression of DP103 can be positioned to be under the axis of 
statins-DP103-NF-κB-metastasis. To further validate our findings and extrapolate to 






Figure 47. Overexpression of DP103 rescues the inhibitory effect of simvastatin 
on invasion. 2 x 10
5
 MDA-MB-231 cells transfected with either empty vector (EV) or 
Flag-DP103 (F-DP103), treated with or without Simvastatin were seeded into the 
upper chamber of the tranwell invasion chamber. After 24h, the membranes of the 
chambers were stained with crystal violet solution and mounted on microscope slides 
(A). Graph showing the percentage of cells that invaded through the membrane (B). 








3.7.3 Simvastatin fed mice showed reduced metastasis and decreased DP103 
expression 
The in vivo model was done in collaboration with Dr Zhu Tao (Hefei National 
Laboratory for Physical Sciences at Microscale and School of Life Sciences, 
University of Science and Technology of China, Hefei, Anhui, P.R. China) to confirm 
the reduction of metastasis upon downregulation of DP103 in mice. 
 
Two groups of 8 female nude mice each were injected into the tail veins with MDA-
MB-231 cells (1 x 10
6
 cells suspended in 200μl PBS) for two weeks. The mice were 
then fed them with either vehicle (DMSO) or 25 mg/kg Simvastatin for a period of six 
weeks before they were sacrificed as described in the materials and methods. 
 
Lung tissues were removed from the mice and stained with H&E to show 
micrometastases. Figure 48A showed pictures of lungs with grossly cystic lung 
micrometastases in the control group. On the other hand, the pictures of lungs from 
the Simvastatin treated group showed significantly fewer visible lung metastases. 
These results were further confirmed by quantifying the number of micrometastasis 
colonies (Figure 48B). Also, the level of human housekeeping gene hypoxanthine-
guanine-phosphoribosyltransferase (hHPRT) was analyzed using real-time PCR as it 
does not cross-react with its mouse counterpart, providing an accurate measure of the 
amount of injected human cells in the mice. A decrease in hHPRT level was observed 
in the Simvastatin treated group mice, indicating a reduction of metastasis of MDA-




We performed immunohistochemistry staining on these lung tissues of the mice and 
showed decreased DP103 and MMP9 expressions (Figure 49), confirming our 
previous observations that Simvastatin decreases DP103 expression in MDA-MB-231 
and thereby reduces cell invasion.  
 
Put together, our hypothesis to use simvastatin to reduce DP103 expression in mice is 
sound and effective. Furthermore, these findings corroborate with our previous in 
















Figure 48. Simvastatin fed mice showed reduced metastasis. 1 x 10
6
 MDA-MB-
231 cells suspended in 200µl PBS were injected into tail vein of female nude mice. 
Groups of 8 mice each were injected intra-peritoneal (i.p.) with either vehicle alone or 
with 25 mg/kg Simvastatin 3 times a week for 6 weeks. Representative hematoxylin 
and eosin staining were shown in (A). The number of metastatic colonies formed were 
quantified and represented in graph (B). To quantify cancer metastasis in mouse 
lungs, qRT-PCR for human hypoxanthine-guanine-phosphoribosyltransferase 
(hHPRT) was performed on Trizol-isolated total RNA using described primers for 







Figure 49. Lung tissues from Simvastatin treated mice showed reduced DP103 
and MMP9 expression. Formalin-fixed, paraffin-embedded lung tissue was cut into 
5 μm section, de-paraffinized in xylene, rehydrated through graded ethanol, quenched 
for endogenous peroxidase activity in 3% (v/v) hydrogen peroxide, and processed for 
antigen retrieval by heating in 10 mM citrate buffer (pH 6.0) at 90-100°C. Sections 














CHAPTER 4  DISCUSSIONS 
 
Breast carcinoma is the most common malignancy among women and its treatment is 
possible if diagnosed at an early stage. The 5-year survival rates for stages 0 to 2 
breast cancer are as high as 99% and 80%, and rapidly decline to 44% and 15% for 
stages 3 and 4. Despite the high survival rates for early stage breast cancer, most of 
such tumors are left unnoticed without regular mammogram tests. Established 
biomarkers such as estrogen receptor (ER), progesterone receptor (PR) and HER2 
have been playing significant roles in the selection and management of patients for 
endocrine therapy. Whilst effective targeted therapeutic modalities exist for women 
with hormone receptor positive and HER2 positive disease, chemotherapy is the only 
systemic therapy available for women with triple-negative cancer.  
 
Triple-negative breast cancer is clearly a distinct clinical subtype, from the 
perspective of hormone receptors and HER2 expression. Additionally, these tumors 
have unique characteristics including increased mitotic activity, high Ki67 index and 
high nuclear-cytoplasmic ratio which are identified in high grade invasive carcinomas 
(Fulford et al., 2006; Livasy et al., 2006; Rakha et al., 2006). The relatively 
aggressive clinical course, poor prognosis (Dent et al., 2007; Haffty et al., 2006) and 
lack of therapeutic options (Thike et al., 2010) for this type of tumors have intensified 
current interest in this patient group and represent an important clinical challenge. 
 
The identification of triple-negative breast cancer currently relies on 
immunohistochemistry and flueorescence in-situ hybridisation (FISH), a process that 
requires strict quality control (Gown, 2008). At the same time, there is no stringent 
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assay or a standard criteria established globally to define accurately this subtype of 
breast cancer. Elucidating more validated prognostic markers for triple-negative 
breast cancer will therefore help in the characterization of patients into the correct 
subgroups.  
 
Prognostic markers are indicators of aggressiveness, invasiveness, extent of spread of 
tumors and thus correlate with survival independent of systemic therapy and can be 
used to select patients at risk. On the other hand, predictive markers predict the 
response of a patient to a specific therapeutic intervention. Patients with early-stage 
breast cancer usually have microscopic metastasis at the time of diagnosis, and 
coupled with the fact that triple-negative breast tumors are associated with more 
aggressiveness (Dent et al., 2007), many molecular markers can therefore be studied 
to elucidate if they possess prognostic or predictive values. 
 
Current treatment strategies for such tumors involve chemotherapy agents such as the 
platinum salts, anthracyclines and taxanes (2005; Andre et al., 2010; Liedtke et al., 
2008; Sirohi et al., 2008). As discussed in the introduction, anthracycline-based 
regimens showed optimistic results of the pathological response rate of the patients in 
studies. Similarly, platinum therapy for triple-negative breast tumor patients displayed 
impressive preclinical results, particularly in tumors also having BRCA mutations. 
However, these therapies require closer scrutiny as focused and large-scale trials have 
not been performed. The increased heterogeneity of tumors in a larger group of 
patients will pose a huge challenge in determining if these drugs will show good 
efficacy in the overall survival and disease-free survival as well as the extent of the 
severity of side effects that these drugs will deliver. 
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A potential prognostic target for triple-negative breast cancer is PARP. Increased 
awareness of PARP can be seen from the rapidity of translation from preclinical 
experiments into clinical advances (Farmer et al., 2005; O'Shaughnessy et al., 2011). 
From preclinical studies, researchers showed that BRCA deficient tumors displayed 
increased sensitivity to PARP inhibitors (Byrski et al., 2008; Farmer et al., 2005), 
sparking off the start of several clinical trials on PARP inhibitors as a single agent or 
in combination regimens in patients with BRCA mutations (Kortmann et al., 2011; 
von Minckwitz et al., 2011). Olaparib (AstraZeneca), a PARP inhibitor, showed an 
overall response rate of 41% among 27 patients assigned to the drug without 
significant toxicity. The use of iniparib (Sanofi), another PARP inhibitor, also 
displayed impressive clinical benefits by prolonging the progression-free survival 
from 3.6 months to 5.9 months when combined with carboplatin and gemcitabine in a 
Phase II trial. As such, PARP inhibitors hold significant potential for the treatment of 
triple-negative breast cancers with minimal toxicity and is likely to be highly tumor 
specific towards the absence of BRCA (Farmer et al., 2005; Tutt et al., 2010).  
owever, it is notable that despite its important role in the cellular response to 
genotoxic stress, PARP1 is not required for survival in the absence of such an insult. 
PARP1
-/-
 mice are viable and fertile (D'Amours et al., 1999; de Murcia et al., 1997).  
 
In view of all these, there remains a fuzzy area for physicians to accurately determine 
the type of therapies to render to the patients. Thus, it sparks off an active interest and 
a pressing need to find novel biomarkers that are unique to triple-negative breast 
cancers as well as novel prognostic markers to determine responsiveness to 




DEAD-box family members belong to the family of RNA helicases and are involved 
in numerous RNA processes (Rocak and Linder, 2004). Several researches have been 
done on different DEAD-box family members on their importance in numerous 
cancers. p68 has been extensively studied to be involved in aberrant post-translational 
modifications in colorectal cancers (Causevic et al., 2001) and is also a transcriptional 
coactivator of the p53 tumor suppressor gene (Bates et al., 2005). On the other hand, 
Ddx3 is involved in the transformation of epithelial to mesenchymal transition via 
downregulation of E-cadherin (Botlagunta et al., 2008), and other members like Ddx1 
and Ddx48 are predominantly overexpressed in retinobastomas and pancreatic cancers 
respectively (Godbout et al., 1998; Xia et al., 2005).  
 
The knowledge of DP103, despite being characterized a decade ago (Grundhoff et al., 
1999), remains few and limited. DP103 was found to be an interacting partner with 
several proteins, including EBNA2 and EBNA3C which regulate transcription of both 
latent viral and cellular genes (Grundhoff et al., 1999); SMN to modulate gene 
expression via pre-mRNA splicing (Zieve and Sauterer, 1990); METS to repress the 
transcription of cell cycle control genes in macrophages  (Klappacher et al., 2002); 
Egr/Krox-20 to repress itself in vertebrate hindbrain (Gillian and Svaren, 2004) and 
FOXL2 to induce apoptosis in Chinese hamster ovary cells (Lee et al., 2005a). 
 
More information on the mechanism of how DP103 represses transcription arose 
during the discovery of the role of DP103 in the development of steroid-producing 
glands and the ventromedial hypothalamus (Ou et al., 2001). DP103 was shown to be 
essential for the co-repression of SF-1, thereby modulating its transcriptional activity 
via SUMOylation modification (Lee et al., 2005b). On top of that, the importance of 
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DP103 physiologically was greatly reflected when it was shown that homozygous 
knockout DP103 mice are embryonic lethal, having failed to develop beyond the two-
cell stage (Mouillet et al., 2008), strongly indicating an essential role in growth and 
development.  
 
Preliminary observations showed that DP103 expression were found to be 
overexpressed in highly proliferating cells, for instance in primary malignant 
melanoma patient tissues (Grundhoff et al., 1999) and lymphoma patients (Ghobrial et 
al., 2005). Microarray analyses also reflected DP103 to be upregulated in lymphoma 
patients (Ghobrial et al., 2005), in CRC patients that developed distal metastases 
(http://www.ebi.ac.uk/arrayexpress [Array express ID: E-GEOD-18105]). 
Additionally, DP103 was found to be a potential target for the inhibition of metastasis 
from a US patent (Publication Number: US 2010/0004190 A1) in 2010. All these 
resulted to the establishment of our hypothesis that DP103 is associated with cancer. 
 
From our tissue microarray results, we found a significant number of patients with 
DP103 being highly expressed in their invasive breast tissues compared to the very 
low expression in their matched normal tissues. This is also seen in the panel of breast 
cell lines representing different status of tumors. While normal breast cells and poorly 
invasive breast carcinomas showed low levels of DP103, it is overexpressed in highly 
invasive breast cancers. It is also necessary to note that the expressions of DP103 are 
higher in the ERα negative cell lines (MDA-MB-231, BT549) as opposed to the ERα 




To demonstrate the relevance of DP103 with tumor progression, we observed the 
DP103 expressions in xenograft-derived cell lines from the MCF10AT series. This 
panel of cell lines are derived from cells from the same parental source at different 
stages of cancer, therefore representing the breast cancer progression model. The 
levels of DP103 are seen to have a positive correlation with increasing degree of 
malignancies, signifying a tight association of DP103 expression with tumorigenesis. 
We verified the same observation in in vivo studies when we tested primary human 
patients samples and immunohistochemical stained them for DP103 expression. 
Tissues that were derived from primary tumors which distal showed metastases were 
revealed to have the highest level of DP103 expression as compared to tumors which 
did not metastasize. 
 
The importance of DP103 in ERα negative breast cancer was elucidated next. While 
the downregulation of DP103 did not affect the viability of the cells, it resulted in 
reduced cell migration, cell invasion and a loss of pseudopodial protusions, all 
demonstrated repeatedly by our various 2D and 3D setups. These symbolize the 
involvement of DP103 in the process of cancer metastasis. Conversely, 
overexpression of DP103 in MDA-MB-231 increased the invasive ability of the cells 
by about 2 folds. More importantly, overexpression of DP103 alone in the normal 
epithelial breast cell line, MCF10A, which displayed very low ability to invade, was 
able to cause the cells to invade by about 4 folds, demonstrating an oncogenic 
function of DP103. 
 
In an attempt to elucidate the genes involved in this downregulation of DP103-
dependent inhibition of metastasis, we performed a metastatic qPCR array and saw 
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MMP9 to be overexpressed by more than 2-fold when DP103 was stably 
overexpressed in BT549. Having found a target gene, we returned to our initial panel 
of different breast cell lines and observed that MMP9 expression was upregulated in 
the same highly invasive cell lines, MDA-MB-231 and BT549 which also showed 
higher DP103 expression. Similarly from our primary human patient breast tissue 
samples, MMP9 expression was revealed to be higher in tumor tissues that had 
metastasized. However, these observations are not unknown since the association of 
MMP9 to cancer invasiveness has long been established (Gong et al., 2000; Kim et 
al., 2006a; van Kempen and Coussens, 2002). Despite that, a novel finding from our 
project is from the correlation studies done using results from the panel of different 
cell lines and the primary human patient breast tissues. We showed strong positive 
association of the levels of DP103 and MMP9 (r = 0.913 and r = 0.513 respectively). 
 
To determine if there is any clinical significance of this newfound association 
between DP103 and MMP9, we retrieved data from 55 breast cancer patients in 
Singapore and selected those showing elevated levels of DP103 expression. In this 
subcohort, patients who were detected with elevated MMP9 levels had poorer overall 
survival (p = 0.029), suggesting strongly that the co-occurrence of high levels of 
DP103 and MMP9 predicted poorer prognosis in patients. This data, however, was 
unable to verify the correlation of these two genes. At the same time, a 'reverse' 
Kaplan Meier analysis in which patients with high MMP9 expressions are selected for 
the determination of survival rate in relation to the levels of DP103 would further 




Since the inhibition of metastasis by DP103 also involved MMP9, we speculated that 
the suppression of DP103 could possibly cause a reduction in MMP9 protein and 
thereby inhibit invasion. This was proven to be true when the protein and mRNA 
levels of this protein was decreased following the inhibition of DP103 by siRNA 
techonology. Additionally, this decrement reflected the loss of MMP9 enzymatic 
activity in our gelatin gel zymography experiment. MMP9 was also revealed to be the 
major endopeptidase to be modulating the inhibition of invasiveness when the 
synthetic inhibitor specific to MMP9 alone was able to suppress the migratory ability 
of MDA-MB-231 across the transwell invasion chamber, a phenotype that could be 
rescued by the overexpression of DP103. After establishing the DP103-MMP9-
metastasis axis, we next explored the signaling pathway in which DP103 is involved 
in to regulate MMP9. 
 
The initiation of activation of signal transduction pathways has been widely 
documented by the interaction of specific ligands with their cell surface receptors. 
This resulted in a cascade of events transmitting signals from the cytoplasm into the 
nucleus, activating transcription factors, ultimately altering gene expressions. Several 
mechanisms had been elucidated to perform these functions. They include GPCR 
(Liggett, 2011), transmembrane signaling by phosphorylation, MAP kinase pathways 
(Zhu et al., 2011), JAK/STAT pathway (Slattery et al., 2011), Wnt/Frizzled pathway 
(Katanaev, 2010), Notch pathway (Bridges et al., 2011), NF-κB pathway (Hayden and 
Ghosh, 2004) and more. Many of these pathways modulate the metastasis cascade. 
  
There is a myriad of transcription factors involved in the regulation of MMP9, some 
of which include AP-1  and NF-κB, both of which act under different physiological 
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conditions depending on the type of stimuli (Adamson et al., 2000; Milde-Langosch et 
al., 2004). A novel and important discovery in our studies is the involvement of 
DP103 in the NF-κB pathway. From our dual-luciferase and EMSA assays, we 
discovered that the down-regulation of DP103 led to a significant decrease in NF-κB 
activity. This decrease in NF-κB activity is specific as the activity of AP-1, another 
transcription regulator of MMP9, is not affected by the suppression of DP103. This is 
further verified when we saw decreased levels of other NF-κB regulated metastatic 
genes like CXCR4 and ICAM1 when DP103 was suppressed. From our 
immunoprecipitation experiments, we observed that DP103 interacts with NEMO, but 
not other NF-κB members like p65, p50 or IκB, and the suppression of DP103 did not 
affect the protein levels of these members. This indicates that DP103 is not regulating 
NEMO and other members at transcriptional level of the NF-κB members. We 
speculated that post-translational modifications may be a possible way that DP103 is 
involved in. Additionally, we observed an increase in DP103 protein levels during the 
induction of NF-κB activity, signifying a possibility that DP103 may itself be an NF-
κB target. It is indeed worth to look further in bid to elucidate the transcriptional 
machinery of DP103 by examining its promoter region for putative NF-κB binding 
sites. 
 
Several post-translational modifications are present in the NF-κB atypical pathway. 
Unlike the canonical pathway, the initiation of this pathway occurs during times when 
cells are exposed to stress from both exogenous and endogenous genotoxic or DNA-
damaging agents. NEMO, as its name suggests, is essential for modulating the 
regulation of the IKK complex. Under the effect of genotoxic agents, DNA double 
strand breaks occur and initiate a series of nuclear post-translational modifications of 
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NEMO before being extruded into the cytoplasm where it complexes with IKKα/β 
subunits to carry out its function to phosphorylate IκBα, releasing the inhibitory effect 
on the NF-κB dimers, p65 and p50, and therefore activating NF-κB in the nucleus 
(Huang et al., 2003). These NEMO post-translational modifications are critically 
required for NF-κB activation as individual mutations in the acceptor sites for these 
post-transcriptional modifications completely block NF-κB activation by multiple 
genotoxic agents (Wu and Miyamoto, 2008). The uniqueness of the atypical NF-κB 
pathway is that the initiation of activation occurs in the nucleus and is transferred to 
the cytoplasm, or namely, the 'nuclear-to-cytoplasmic' signaling pathway.  
 
As discussed previously, triple-negative breast cancers with BRCA mutations are 
more susceptible to DNA damaging agents (Farmer et al., 2005). A connection 
between this susceptibility and aberrant NF-κB activation via the DNA-damage-
dependent atypical pathway in breast cancers may be plausible. Understanding the 
mechanism may provide a deeper insight of the physiological roles of various 
molecules in this signaling event, especially that in breast cancers and at the same 
time shed light into the search for a probable therapeutic target for breast cancers as 
well as other cancers.  
 
Besides establishing that NF-κB activity was reduced in the absence of DP103, we 
also demonstrated similar decrease in NF-κB activity upon different genotoxic 
stimuli, doxorubicin, camptothecin and etoposide which are known activators of NF-
κB. Since we previously showed DP103 does not modulate NF-κB members at the 
transcriptional level and that it interacts with NEMO, we hypothesized that DP103 
regulates the activity or function of NEMO via post-translational modifications. 
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NEMO undergoes several post-translational modifications in the atypical pathway, 
including the translocation of free cytoplasmic NEMO into the nucleus, SUMOylated, 
phosphorylated and subsequently ubiquitinated. The addition of Ub groups onto 
NEMO causes it to be extruded into the cytoplasm and enters the canonical pathway 
to activate NF-κB. A plausible connection can be drawn here from the fact that 
DP103 acts as a co-repressor for SF-1 via SUMO modification (Lee et al., 2005b; Ou 
et al., 2001). 
 
As SUMOylation is a rapid and reversible process, it is difficult to detect the levels of 
SUMOylated NEMO under basal conditions. Additionally, the SUMOylation process 
cannot be separated from the deSUMOylation process. To overcome the limitation of 
a relatively low percentage of SUMOylation that has significant effects on many 
biological processes, we employed the use of genotoxic drugs, doxorubicin, 
camptothecin and epotoside to enhance the SUMOylation of NEMO (Huang et al., 
2003). We showed DP103 to be essential for the SUMOylation of NEMO under 
camptothecin stimulus due to an increase seen in SUMOylated NEMO. In addition, 
downregulation of DP103 halts this post-translational modification, both basal and 
with genotoxic stimuli, thereby inhibiting NF-κB activation. The paramount 
significance of this finding is that for the first time, we elucidated DP103 to be a 
critical regulator for the SUMO modification of NEMO. 
 
As DP103 belongs to the family of RNA helicases, the involvement of the helicase 
activity in the SUMOylation of NEMO is of interest. In this family of RNA helicases, 
ATP is required for the unwinding of RNA and several members are known to display 
both ATP-dependent as well as ATP-independent functions (Bates et al., 2005; 
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Botlagunta et al., 2008; Chao et al., 2006; Rocak et al., 2005). In our study, we 
demonstrated that the helicase activity of DP103 is dispensable for this SUMO 
modification. Cells transfected with the helicase dead GNT mutant showed no 
difference in the SUMOylation strength of DP103 to NEMO and did not affect the 
cells' invasion ability. This is in concordance to previous findings that DP103 helicase 
activity is not required for SUMOylation of SF-1 to occur (Lee et al., 2005b; Ou et al., 
2001). 
 
SUMOylation is a highly dynamic and coordinated process, and is involved in a 
variety of cellular processes for growth, development, apoptosis as well as cancer 
metastasis (Bettermann et al., 2011; Hirata et al.; Kessler et al., 2011; Pot and Bonni, 
2008). However, many basic questions regarding components, mechanisms and 
consequences remain unanswered. For instance, the list of characterised enzymes 
appear to be short considering the large number of target proteins that are modified in 
a regulated manner. Additionally, there may be many SUMO enzymes that are not 
discovered yet, as well as regulatory elements like co-factors involved in 
SUMOylation and deSUMOylation. Knowledge of how SUMOylation is involved in 
metastasis is also limited, despite the increasing focus in this area in recent years. It is 
particularly important to note that in prostate cancer, the levels of endogenously 
SUMOylated reptin protein in metastatic prostate cell line LNCaP was found to be 
higher compared with that in the normal prostate epithelial cells RWPE1. 
Furthermore, the expression levels of Ubc9, SUMO E2 enzyme were increased in 
metastatic cancer cells while the levels of deSUMOylating enzyme SENP1 was 
reduced (Kim et al., 2006b; Kim et al., 2005). It is thus speculated that proteins 
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regulating the expression levels of these SUMO enzymes are also associated to the 
progression of cancer metastasis.  
 
To validate our hypothesis, we performed a pull-down assay and observed the 
interaction of DP103 with PIASy and SENP2, but not SENP1. Together with our 
previous results, DP103 fits all the descriptions to be the regulatory protein in 
SUMOylation. We went on to perform an in vitro SUMOylation assay and showed 
that the addition of both DP103 and PIASy further enhanced NEMO SUMOylation 
compared to PIASy alone. This observation is similar with the study done by Lee et 
al., 2005b in that DP103 increased PIAS-dependent SF-1 SUMOylation. Moreover, 
our immunoprecipitation experiments highlighted that the interactions between 
DP103 and NEMO, and NEMO and PIASy were progressively enhanced upon 
expression of increasing amounts of DP103, indicating an increase in the levels of 
NEMO SUMOylation. 
 
On the other hand, the possible role of DP103 in inhibiting deSUMOylation of 
NEMO cannot be overlooked. We demonstrated the substrate specificity to SENP2 
when DP103 was observed to interact with it but not SENP1 in the pull-down assay. 
However, the addition of both SENP2 and DP103 in the in vitro SUMOylation assay 
did not abolish the deSUMOylation effect of SENP2. Despite this, we found the 
interaction between NEMO and SENP2 to be decreasing with increasing levels of 
DP103. Put together, DP103 prevents the interaction of NEMO and SENP2 to occur, 




Although Lee et al., 2005 first described the role of DP103 in SUMOylation, there are 
several novel facets that our study has uncovered. First, unlike our study which shows 
that genotoxic stress mediated SUMOylation reaction is aided by DP103, no 
physiological stimuli was identified which aided this reaction towards SF-1. Second, 
while SUMOylation of SF-1 can repress transcription, SUMOylation of NEMO 
promotes activation of NF-B dependent transcription. Finally, in contrast to 
SUMOylation of SF-1 by DP103 that can directly regulate gene expression, 
SUMOylation of NEMO affects activity of a kinase complex, namely the IKK 
complex, which may have other substrates besides IB and hence DP103-mediated 
SUMOylation of NEMO has the potential to affect other signaling mechanisms in 
cancer. 
 
p68, another member of the DEAD-box family, has been found to be able to function 
as both a transcriptional activator and repressor. SUMOylation of itself proved to hold 
the delicate call to which function p68 should perfrom. A K53R mutant of p68 that 
renders it unSUMOylated is unable to interact with HDAC1 and hence a more 
effective co-activator (Moore et al., 2010). The SUMOylated form of p68, on the 
other hand, is an efficient transcriptional repressor (Bates et al., 2005). Though DP103 
had not been shown to be SUMOylated for the modulation of its own activity, the 
presence of a SUMOylation interacting motif (SIM) at its C-terminal may be an 
indication for such a possibility. This will be important for future works as a tool for 





Our findings thus far revealed DP103 to be a prognostic marker for breast cancer 
metastasis and that its suppression will lead to reduced cell invasion. At the same 
time, we showed a mechanism by which this inhibition occurred via SUMO 
modification of NEMO in the atypical NF-κB pathway. Importantly, this 
downregulation of DP103 increased the susceptibility of the cells to genotoxic stress 
from our viability studies where cell death was increased by about 30% compared to 
the cells treated with camptothecin or doxorubicin alone, or with suppression of 
DP103 alone. These provide a foundation for mouse models or possibly preclinical 
trials to be set up to validate the efficacy of this combinatorial therapy for the 
treatment of triple-negative breast cancer. 
 
A limitation in our suggested combinatorial therapy is the method to suppress DP103 
in invasive cells. In our project, we had been using the small interfering RNA 
technology to reduce the DP103 expression. However, systemic use of siRNA for 
therapies is still controversial due to the limitations of siRNA such as low enzymatic 
tolerability, cellular internalization and body distribution after systemic administration 
(Guo et al., 2010; Pirollo and Chang, 2008; Tamura and Nagasaki, 2010). Moreover, 
because intact, functional siRNA must be delivered into the target cell to reach an 
effective intracellular concentration, the problem of potential side effects due to 
general transfection of normal, nontarget tissues must be addressed critically. In order 
to overcome this, we attempted to use a commercially available therapeutic drug to 
produce the same effect as that of the siRNAs. 
 
Statins have been used clinically for the treatment of hypercholesterolemia. They act 
by inhibiting the rate-limiting enzyme of the mevalonate pathway, 3-hydroxy-3-
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methylglutaryl-CoA reductase. Despite that, statins have been shown to demonstrate 
anti-cancer properties over the years (Denoyelle et al., 2001; Kang et al., 2009; Li and 
Brown, 2009). Importantly, simvastatin and lovastatin are able to inhibit breast cell 
invasion with a reduction in MMP9 and MMP2 protein expressions (Kang et al., 
2009; Mandal et al., 2011). Furthermore, Aberg and group described induction of 
apoptosis by simvastatin to happen via inhibition on the NF-κB pathway (Aberg et al., 
2008). Other studies have also attributed effects of simvastatin like attenuation of 
growth and malignant potential in esophageal adenocarcinoma (Sadaria et al., 2011), 
reduction in pulmonary artery hypertension (Liu et al., 2011) and cardioprotection 
from ischemic-reperfusion injury (Malik et al., 2011) to be through the suppression of 
NF-κB activity.  
 
With these knowledge, we hypothesized that statins inhibit invasion in breast cancers 
through inhibition of DP103-dependent NF-κB activation. Our results showed that 
simvastatin decreased DP103 levels at the transcriptional level and inhibit invasion. 
NF-κB-regulated metastatic genes, CXCR4 and MMP9 were also reduced in a dose-
dependent manner under statins treatment. Furthermore, forced expression of DP103 
upon simvastatin treatment abrogated this effect. Added evidence came from our in 
vivo studies, where similar observations were seen from nude mice that were injected 
with MDA-MB-231 cells. Mice that were fed with simvastatin showed lesser lung 
metastases as compared to the vehicle. Immunohistochemical staining of tissues 
extracted from these metastases revealed a decrease in DP103 as well as MMP9 
expressions, confirming our hypotheses and mechanism of action. Hence, we 
demonstrated, for the first time, a direct link of statins-DP103-NF-κB-metastasis on 
the same axis in breast cancer cells. 
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Putting all our findings together, a signaling cascade with or without genotoxic 
stimuli that involves DP103, NEMO and NF-κB is proposed (Figure 50). In resting 
cells there is likely a competition between PIASy and SENP2 to bind the substrate, 
NEMO. Under conditions when DP103 levels are limiting, such as in normal cells, we 
speculate that it is the interplay between these factors that keeps SUMOylated NEMO 
levels under equilibrium and prevents constitutive activation of NF-κB and metastatic 
switch. In contrast, in cancer cells when DP103 levels become high (due to genetic or 
epigenetic changes), DP103 prevents the binding/recruitment of SENP2 to the 
substrate (NEMO). This then allows PIASy to bind and SUMOylate NEMO, a 
reaction that is also aided by DP103. In effect, these dual activities of DP103 could 
make NEMO more prone to constitutive SUMOylation and hence contribute to NF-
κB constitutive activation in cancer cells. 
 
Given that constitutive activation of NF-κB can also lead to the acquisition of 
resistance to chemotherapy, a hallmark of highly aggressive cancers, DP103-mediated 
NF-κB activation could not just be providing a metastatic switch to cells but also 
making tumor cells acquire other factors that govern carcinogenesis, namely ability to 
resist death and also reprogram metabolism (Mauro et al., 2011), both of which are 
also now known to be regulated by NF-κB activity. Indeed reduction of NF-κB 
signaling by downregulating DP103 sensitizes them to chemotherapy induced cell 
death.  
 
Although constitutive activation of NF-κB is a well-documented phenomenon in 
cancer, increased levels of enzymes such as PIASy that can keep NEMO in a 
constitutively active state are not seen in cancer cells. Indeed it is highly tempting to 
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speculate that the levels of PIASy are not limiting in cancer cells but since the levels 
of DP103 are, it is the increase in levels of DP103 that marks the switch from a non-
metastatic to metastatic state in a number of cancer cells. How this switch in DP103 
expression occurs is a fundamental unanswered question that must be addressed in the 
future. Furthermore, understanding what turns on and keeps levels of DP103 high in 
cancer cells will provide us with a new set of therapeutic targets. Also what 
reprogramming a cancer cell undergoes to live with elevated levels of a RNA helicase 








Figure 50. Proposed model of DP103 regulation in NF-κB atypical signaling pathway. DP103 associates with NEMO and 
mediates the SUMOylation of NEMO in a PIASy-dependent manner under genotoxic stress, progressing down the cascade to turn on 
NF-κB activation. SENP2 interaction with NEMO, at the same time, was decreased in the presence of DP103. DSB denotes DNA 
double strand break. 
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CHAPTER 5  FUTURE DIRECTIONS AND CONCLUSIONS 
 
Our work starts with the interesting observation that DP103 is upregulated in highly 
proliferating cells, and particularly in metastatic breast cancer cells. Further in vitro, in 
vivo and functional works allowed us to support, for the first time, an unsuspected role of 
DP103 in cancer metastasis through modulation of the NF-κB pathway. Hereby, we 
present evidence to the role of DP103 in the NF-κB atypical signaling pathway. It is also 
the first detailed report describing the regulation of NEMO SUMOylation. 
 
The possible clinical applications of our findings cannot be overemphasized. As DP103 
expression correlates with the state of malignancies, it can be used as a prognostic marker 
to define breast cancer patients at the risk of developing metastases. Due to the 
heterogeneity of tumors, the response from breast cancer patients may not be complete. 
Predictive markers are of importance to accurately determine if certain treatment will be 
effective, as well as receiving the correct treatment early to eradicate the tumor. The 
potential of DP103 as a predictive marker for therapeutic intervention will thus be of 
immense interest. 
 
NF-κB signaling pathway is an important pathway regulating cancer progression at many 
levels. At the same time, the persistent activation of NF-κB is observed in the highly 
aggressive breast cancers as well as in tumors acquiring resistance to drug treatments. 
Despite these knowledge, members in the NF-κB family are not 'druggable' as basal NF-
κB activity is required for normal physiological responses like transcription of related 
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genes during stress, immune responses during microbial attacks or for survival especially 
in tumors. Therefore, targeting molecules involved in the regulation of NF-κB activation 
will be more probable. 
 
As an essential regulator of NEMO SUMOylation in the NF-κB pathway, DP103 plays a 
critical role in modulating the transcriptional activity of NF-κB. In order to ensure 
thorough consistency on our findings using different techniques, further experiments can 
be done for validation. For example, the SUMOylation levels of NEMO in different 
breast cell lines can be done to confirm that increased SUMO modification occurs in 
malignant cells, as well as to draw stronger correlation to the levels of DP103.  
 
Further experiments can be done to map the site(s) of interaction between DP103 and 
NEMO. It is likely to involve the C-terminal region of DP103, given that previous studies 
had shown numerous interactions between the C-terminus and its target substrates 
(Charroux et al., 1999; Grundhoff et al., 1999). At the same time, this will shed light into 
whether DP103 and SENP2 bind to NEMO on the same residue. Put together, knowledge 
of this interaction provides a potential clinical application to design small molecule 
inhibitors to competitively block the interactions and hence, inhibit NF-κB transcription. 
 
A long term implication of our findings is the possibility of an effective combinatorial 
therapeutic intervention using simvastatin (or other drugs to suppress DP103) and a 
genotoxic agent for the treatment of aggressive triple-negative breast cancers. 
Simvastatin reduces DP103 expression, which increases the susceptibility of the cancer 
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cells to genotoxic agents, thus killing the cancer cells. However, more studies will need 
to be carried out to confirm, validate and test for efficacy and toxicity of such 
combinatorial therapy. It is worthy to remind that DP103 expressions are low in normal 
breast tissues and therefore, this can be used as a targeted therapy towards metastatic 
cancers without possibly causing severe side effects. 
 
We extended our study to other types of cancer and found that downregulation of DP103 
also inhibit the invasiveness of cells in prostate cancer cell line PC3 and in colorectal 
cancer cell line HCT116 (data not shown, included in patent). As such, extrapolation of 
the role of DP103 into these cancers is worthy be explored further. 
 
In conclusion, we uncover a novel role of DP103 in cancer metastasis and show it to be a 
co-activator in transcription. At the same time, we reveal DP103 to be critically important 
in the SUMO modification of NEMO and for the first time, a co-regulator in this 
pathway. Our findings in this project brings about a plethora of possibilities to further 
unravel different functions of DP103 in tumorigenesis. On the other hand, the study of its 
role in hormone-positive breast cancer is also of our interest and is currently underway in 
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Sequences of primers used in metastatic qPCR array 
Gene Abbreviation Primer Primer Sequence (5' → 3') 















cells 1, protein 

















































TIMP1 Forward CTTCTGGCATCCTGTTGTTG 
Reverse AGAAGGCCGTCTGTGGGT 
Metastasis 










TIMP3 Forward CCAGGACGCCTTCTGCAAC 
Reverse CCTCCTTTACCAGCTTCTTC
CC 
 
 
